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1. Summary
Transgenic animals are generated by injection of recombinant DNA sequences into
fertilized oocytes. Here I applied a new methodology for the generation of transgenic
knockdown mice using the LentiLox 3.7 lentivirus as a transfer vehicle bearing an U6-
promoter dependent shRNA expression cassette. Lentiviruses are a sub-class of retroviruses
that have the capability to infect non-dividing post-mitotic cells. Recently, in addition to
their use to transform primary cells and established cell lines, lentiviruses have also been
used to generate transgenic mice, pigs, cattle, rats and chickens. Thus, we hoped that
lentiviral vectors containing U6/RNAi expression cassettes could serve as a fast and
attractive alternative for the generation of mice with reduced expression of specific genes.
As a model for this in vivo knockdown approach I chose the hepatocyte nuclear receptor 4 γ
(HNF4γ)  for which a knock out model was not available. Expression analyses of the
HNF4γ gene demonstrated synthesis of the protein in the embryonic gut at day E16.5. In
adult animals its expression is restricted predominantly to the differentiated, absorptive
brush border cells of the small intestine (enterocytes) and to the cells of pancreatic islets
(islets of Langerhans). In order to knockdown the HNF4γ gene, a panel of five shRNA
hairpin sequences was selected by the public Sirna software and their activity was validated
by transfection  experiments in cell culture. After re-cloning of the U6/shRNA cassettes into
the pLL 3.7 vector, infectious virus particles were generated and injected within the
perivitelline space of one cell stage mouse embryos.  56% of the LentiLox 3.7 lentivirus
founder mice were PCR-positive, however expression from the transgene was highly
mosaic. The high mosaicism of F0 mice precluded their use for immediate expression
analysis as it was hoped when the project was started. The high degree of  mosaicism is also
reflected by a low rate of germ line  transmission. Only 6% of F1 mice expressed the
indicator gene for EGFP as well as the shRNA transgene. Often expression was not
ubiquitous probably reflecting the dependence of expression on the chromosomal
integration site.  A good correlation between EGFP  activity and siRNA  accumulation in
organs of F1 mice was found as  evidenced by Northern blot hybridisation. Despite the
general low efficiency of transgenesis the down regulation of HNF4γ gene in one F1 line
(A-I) reached 50% in the gut and 80% in pancreas proving that this targeted knockdown
approach is working in living animals.                          .
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1. Zusammenfassung
Transgene Mäuse werden durch Mikroinjektion von rekombinanter DNA in Oocyten
erzeugt. In dieser Arbeit erzielte ich eine Geninaktivierung in transgenen Mäusen durch
Verwendung des lentiviralen Expressionsvektors LentiLox 3.7, der eine durch den U6-
Promotor kontrollierte Expressionskassette enthält. Lentiviren sind eine Unterklasse von
Retroviren, die auch nicht in Zellteilung befindliche Zellen infizieren können. In letzter Zeit
wurden lentivirale Vektoren, zusätzlich zu ihrer Verwendung in primären Zellen und
permanenten Zellinien, auch zur Herstellung von transgenen Mäusen, Ratten, Schweinen,
Rindern und Hühnern benutzt. Wir hofften, lentivirale Vektoren mit einer U6/RNAi-
Expressionskassette könnten als attraktive schnelle Alternative für die Erzeugung von
Mäusen mit einer reduzierten Expression spezifischer Gene verwendet werden unter der
Vorstellung, dass die transgenen Mäuse dann ohne weiter Züchtung direkt analysiert
werden könnten. Als Modell für dieses Vorgehen habe ich den hepatozytenspezifischen
nukleären Faktor 4γ, HNF4γ, gewählt, da für dieses Gen kein knock out-Modell existierte.
Expressionsanalysen zeigten, dass das HNF4γ-Protein im embryonalen Darm ab E 16.5
exprimiert wird. In adulten Tieren ist die Expression auf die differenzierten
Bürstenepithelien (Enterozyten) des Dünndarms und auf Inselzellen im Pankreas
(Langerhanssche Inseln) beschränkt. Zur Inaktivierung des HNF4γ-Gens wurden fünf
unterschiedliche shRNA-Sequenzen mit Hilfe der allgemein zugänglichen Sirna-Software
ausgesucht und deren Aktivität durch Transfektion in Zellkultur getestet. Nach
Umklonierung der U6/shRNA-Kassette in LentiLox 3.7 wurden infektiöse Partikel erzeugt
und in den perivitellaren Raum von Mausembryonen (Einzell-Stadium) injiziert. In 56% der
Mäuse aus den injizierten Embryonen (F0) konnte durch PCR ein positiver Nachweis für
das virale Transgen geführt werden, die Expression des Transgens war aber sehr mosaik-
artig. Der ausgeprägt mosaike Expression in F0-Mäusen verhinderte ihre Verwendung für
eine direkte Analyse von HNF4γ−Defizienz, wie es zu Beginn des Projektes erhofft wurde.
Der hohe Grad von mosaiker Expression spiegelte sich auch in der geringen Rate von
Keimbahntransmission wieder. Nur 6% der F1-Mäuse exprimierte das Indikator-Gen EGFP
sowie shRNA. Häufig war die Expression nicht ubiquitär, was vermutlich eine
Abhängigkeit der Expression des Transgens von der chromosomalen Integrationsstelle
anzeigt. Northern-Hybridisierung zeigte aber eine gute Korrelation zwischen der Intensität
ZUSAMMENFASSUNG
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des EGFP-Signals und der Akkumulation der siRNA als Produkt der U6/shRNA-
Expressionskassette. Trotz der allgemein niedrigen Effizienz der Transgenese war die
Expression von HNF4γ-RNA in einer der F1-Linien (A-I) im Dünndarm um 50% und im
Pankreas um 80% reduziert. Dies zeigt, dass die gewählte Methode zur Geninaktivierung
prinzipiell auch in Tieren anwendbar ist, allerdings mit einer niedrigen Effizienz und ohne
Zeitvorteil gegenüber der konventionellen knock out-Technologie.
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2. Introduction
2. 1.  Nuclear receptor transcription factors
Nuclear receptors function as ligand-activated transcription factors that regulate the
expression of target genes and that are involved in the control of a diversity of cellular
processes. Nuclear receptors are localized in the cytoplasm and/or nucleus. Their ligands are
lipophilic molecules which either diffuse through the cell membrane or they are intracellular
metabolites. Both types bind to their cognate receptors, thereby modulating their activity.
The ligand-activated receptors then bind to DNA elements in the control region of target
genes or modulate by protein-protein interaction the transcription of the target genes and
thus transform extracellular and intracellular signals into a change of gene expression [1].
Currently, the human genome is reported to contain 48 members of the nuclear receptor
family [2]. This super-family includes not only the typical endocrine receptors that mediate
the actions of steroid and  thyroid hormones as well as of fat-soluble vitamins A and D [1],
but includes also the so-called orphan nuclear receptors, whose ligands, target genes, and
physiological functions were initially unknown [3]. Many of the receptors are lipid sensors
that response to cellular lipid levels and regulate metabolic activities or promote gene
expression changes to protect cells from lipid overload [2].
2. 1. 1.  Structure of nuclear receptors
The nuclear receptors have common structural features and are currently grouped into six
different subfamilies [4]. They display a high degree of homology at the level of amino acid
sequence which indicates similar functional principles. The nuclear receptors have a
modular structure with autonomous functional domains. At the level of primary structure,
five domains can be distinguished each with specific functions [4].
A typical nuclear receptor consists of the variable N-terminal A/B region, a highly
conserved domain responsible for DNA binding (C region), D region with nuclear
localization signal, the ligand binding and dimerization domain (domain E) and an F region
(Figure 1). Domains responsible for trans-activation are found in the A/B region (activation
function 1, AF-1), and in the E region (activation function 2, AF-2) [5].
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_________________________________________________________________________
5
2. 1. 2.  HNF4γ
HNF4γ is a member of the nuclear receptor family the function of which is unknown,
because a mutation of this gene has not been generated yet. HNF4γ is highly homologous to
the previously characterized HNF4α; however their chromosomal localizations are distinct
[6]. HNF4γ orthologues were identified in other organisms: DHNF4 (Drosophila HNF4)
[7], XHNF4 (Xenopus HNF4β) [8]. The natural ligands for HNF4γ are fatty acids [9]. It
was hypothesized that HNF4γ may have a role in regulation of an apoA-I/C-III/A-IV gene
cluster expression in the intestine [10].
HNF4γ has the typical structure of nuclear receptors: the A/B domain contains
transactivation activity, the C region contains two zink fingers responsible for DNA
binding, the E ligand binding domain, the F region with regulatory functions (Figure1) [6].
Figure 1. The protein structure of HNF4γ
Schematic representation of the HNF4γ protein: trans-activation domain (A/B); DNA binding
domain (DBD); ligand binding domain (LBD); regulatory domain (F).
The structures of several orphan nuclear receptors, including human HNF4γ, peroxisome
proliferators-activated receptor delta (PPARδ), retinoic acid-related orphan receptor β
(RORβ), and a constitutively active mutant RXR  were obtained as a complex with various
naturally occurring lipids [11]. However, all of these nuclear factors have significant
differences in their ligand binding pocket when compared with the HNF4γ binding pocket.
The HNF4γ pocket is almost exclusively hydrophobic, with the exception of the conserved
arginine that interacts directly with the fatty acid. Palmitic acid almost completely fills the
HNF4γ binding pocket, leaving no room for additional bound water molecules. The HNF4γ
structure showed the fatty acid with its acid head-group forming a hydrogen bond with a
conserved arginine in helix 5. This prevents a direct interaction between the fatty acid and
the AF2 helix [12]. The HNF4γ binding pocket is small (626A). The HNF4γ/α can only
bind C14-18 saturated and monounsaturated fatty acids, with the ligand almost completely
filling the pocket (Figure 2) [11].
DBD LBD F
22 88 339
A/B
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Figure 2: Structure of the HNF4γ ligand binding domain and the HNF4γ binding pocket
(A) Diagram of HNF4γ with bound palmitate. Palmitate has dark gray carbon atoms and red
oxygen atoms.
(A) Model showing proposed interactions between palmitic acid and the HNF4γ binding pocket.
HNF4γ atoms are yellow except for arginine 187 (blue). Palmitic acid has white carbons and
red oxygens. The surface on the inside of the pocket is shown in green. C16-18 fatty acids
fully occupy the pocket. (modified from G. Wisely; [11])
It was found that HNF4γ-bound fatty acid is sufficient to promote interaction with nuclear
receptor co-activators. The attempts to measure HNF4γ ligand exchange with radiolabelled
palmitic acid showed that either exchange does not occur or the rate is extremely slow
under the conditions used. It can be speculated that the fatty acids undergo incorporation
through a selection process during HNF4γ translation and folding and then are trapped in
the fully folded protein. Moreover, the fatty acid does not behave like an exchangeable
ligand, but rather as a structural cofactor for HNF4γ [11-12].
In co-transfection experiments in Hela and COS cells, HNF4γ was able to activate
transcription, acting through binding sites that have been previously characterized as
HNF4α binding sites for the apolipoprotein CIII and the TAT gene. mHNF4γ was able to
activate transcription at low levels (50ng) and trans-activation reached a plateau when
250ng of the expression plasmid was used which was 3-fold above basal level (Figure 3)
[6].
B
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Figure 3: Transcriptional activation by
mHNF4γ
(A) Increasing amounts (50-100ng) of
expression vector containing the
mHNF4γ cDNA (pCMVm HNF4γ)
were co-transfected into HeLa cells
with a CAT reporter construct
containing a HNF4α recognition site
from the apolipoprotein CIII gene
promoter (pAPFIHIVCAT). The bars
represent CAT activity, while CAT
activity when no expression vector
was transfected was used as a
background control.
(A) mHNF4γ can function as a
transcriptional activator through the
tyrosine amino transferase (TAT)
HNF4α  binding sites. The reporter
gene pBLCAT2xHNF4 contains an
HNF4 binding site from the TAT
gene as a dimer which was
transfected into COS cells together
with 250ng of the expression vector
carrying the mHNF4γ  cDNA
(pCMVmHNF4γ) (Taraviras).
INTRODUCTION
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2. 2.  RNA interference
RNA silencing or RNA interference [13] (RNAi) occurs in a wide variety of eukaryotic
organisms [14,15]. It is mediated by dsRNA precursors that differ in length and origin.
These dsRNA are rapidly processed into short RNA duplexes of 21 to 29 nucleotides, which
then are incorporated into the RNA-induced silencing complex (RISC) leading to cleavage
or translational repression of complementary, single-stranded RNAs, such as messenger or
viral genomic RNAs [16].
According to their origin or function, three types of small RNA have been described: short
interfering RNAs (siRNAs), repeat-associated short interfering RNAs (rasiRNAs) and
microRNAs (miRNAs). In cells, dsRNAs are produced by RNA-templated RNA
polymerization (from viruses) or by hybridization of overlapping transcripts (transgene
arrays and transposons). Such dsRNAs give rise to siRNA or rasiRNAs, which guide
mRNA degradation or/and chromatin modification. Otherwise, cellular transcripts that
contain complementary or near-complementary 20- to 50-base-pair inverted repeats fold
back to form dsRNA hairpins. These dsRNA are then processed into miRNAs that mediate
translational repression and in rare cases mRNA degradation [16].
RNAi silencing was first recognized as an antiviral mechanism that protects organisms from
RNA viruses [17], or which prevents the random integration of transposable elements. Later
this perception was expanded by the finding that dsRNA can induce silencing in Drosophila
[18], C. elegans [13,19, 20] and in other organisms that were otherwise not easily accessible
to genetic analysis [21, 22]. Small RNAs were shown to be generated in plants and were
found as products of the RNA silencing pathway [23]. The dsRNA-processing enzyme
Dicer [24] was identified to produce these small RNAs, now called short interfering RNAs
(siRNA). Synthetic RNAs engineered as Dicer products were shown to be capable to induce
sequence-specific gene silencing in human cells without initiating non-specific gene
silencing pathways [25]. A class of natural hairpin dsRNAs (miRNAs) [26, 27] was shown
to be processed by Dicer [28-30] and to function together with RDE-I homologues [30],
thereby linking the RNAi machinery to natural developmental gene regulatory mechanisms.
More recently, the RNAi was also linked to chromatin regulation in yeast [31] and to
chromosomal rearrangement during development of the somatic macronucleus in
Tetrahymena [32].
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2. 2. 1.  siRNA and microRNAs (miRNA)
miRNAs are highly related to siRNAs. They are endogenous small RNAs that repress the
expression of target genes. miRNAs differ from siRNA in their biogenesis, not in their
functions [33-39]. Similar to siRNA, plant and animal miRNAs can direct cleavage of
mRNA targets when both show extensive sequence complementarity [40-44], but repress
mRNA translation when complementarity is less [45, 46]. The sequence of miRNA or of
siRNA determine how effectively it might act by direct cleavage or by translational
repression.
Both siRNAs and miRNAs can also trigger methylation of DNA of protein-coding genes
that share sequence in plants [47, 48] and most likely in mammals [49, 50]. siRNA can
direct the construction of repressive heterochromatin, namely centromeric heterochromatin
[51-55]. As a class, miRNA and siRNA guide strands are functionally indistinguishable, but
it is still not clear whether all miRNA and siRNA sequences are capable of effectively
guiding all RNA silencing functions.
Natural miRNA are derived from long primary RNAs (pri-miRNAs) transcribed by RNA
Polymerase II [56-58]. Animal viruses also can encode miRNA [59, 60]; these may be
transcribed by RNA Polymerase II or III. Pri-miRNA contain stem-loop structures that
harbour the miRNA [61]. In animals, the stem-loops are around 70nt long, and Drosha, a
nuclear RNase III-type endonuclease, liberates the stem-loop from the primary transcript to
yield a pre-miRNA [62]. The pair of cuts made by Drosha establishes one end of the
miRNA [63][62]. In this process, Drosha participates with a double stranded RNA binding
protein, called Pasha in flies and DGCR8 in humans [64-67]. The pre-miRNA liberated by
Drosha is exported from the nucleus by the protein Exportin 5 [68-70], then cut by Dicer in
the cytoplasm to produce the mature miRNA [28-30]. In some organisms, such as worms
and man, the same Dicer that makes siRNA, processes pre-miRNA; in plants and flies,
different Dicer paralogs make siRNA and miRNA [71].
Each miRNA or siRNA duplex can potentially yield two single-stranded 21nt RNAs
capable of directing RNA silencing, but only one of them usually accumulates as mature
siRNA (guide)  in RISC complex (Figure 4). The passenger strand is usually destroyed[56].
INTRODUCTION
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Figure 4: Small RNA biogenesis in animals
(A) miRNA are produced by the action of two RNase III ribonucleases. After their transcription
by RNA pol II, primary miRNA (pri-miRNA) are cleaved in the nucleus by Drosha, which
is in heterodimeric complex with the dsRNA-binding protein. Drosha cleavage generates
the pre-miRNA, which binds Exportin 5 and is exported to the cytoplasm.
(A) Long dsRNA is a substrate for Dicer, but not for Drosha. Dicer must make two pairs of cuts
to yield an siRNA duplex. Dicer is thought to preferentially initiate dsRNA cleavage at the
end of dsRNA, which some times produces a phased string of siRNAs along the dsRNA.
The RISC machinery selectively loads the guide strand into RISC; the passenger strand is
degraded. (modified from Tomari [56])
2. 2. 2.  Selection of highly effective siRNA sequences
Recently Khvorova and colleagues [72] used informatical methods to understand which
siRNA strand enters the RISC as the guide and which is excluded and becomes passenger
strand by comparing the thermodynamic profiles for hundreds of siRNAs- active and
inactive. The thermodynamic signatures of siRNAs provide a graphical representation of
how tightly base-paired one siRNA strand is to its complement at each position of the 19-bp
helix that links the two strands (Figure 5). The local thermodynamic stability of nucleic acid
helices is a function of the base pairs flanking an individual G:C or A:U base pair in an
RNA helix. Thus, a “nearest-neighbour” analysis can predict the local stability at each
position in a siRNA. Several reports provide so-called „design rules“ to distinguish
functional from non-functional siRNA [73-75].
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Figure 5: The generation of effective siRNA
A small interfering RNA (siRNA) is a 21-23nt dsRNA that contains: a 19-nt duplex region,
symmetric 2-3-nt 3´ overhangs and 5´ -phosphate (P) and 3´ -hydroxyl (OH) groups. The effective
siRNA has high stability at the 5´ terminus of the sense strand (blue box), lower stability at the 5´
antisense terminus (orange box) and the cleavage site (purple box). The sequence-specific
preferences at the following positions on the sense strand are important: an A at position 19, an A at
position 3, a U at position 10.
2. 2. 3.  RISC function
Once loaded into RISC, the small RNAs guide at least three distinct modes of silencing. In
the RNA pathway, small RNAs direct RISC to cut target RNAs. The cleavage by RISC
requires Mg2+, leaves 3´ hydroxy and 5´ phosphate termini, and is inhibited by
phosphorothioates at the scissile phosphate, all hallmarks of a role for Mg2+ in the catalysis
[76-78]. The cleavage is thought to be catalyzed by the Piwi domain of a subclass of
Argonaute proteins [78][79]. This domain is a structural homolog of RNase H, a Mg2+ -
dependent endoribonuclease that cleaves the RNA strand of RNA-DNA hybrids [80].
Unlike RNase H, each cleavage-competent RISC can break only one phosphodiester bond
in its RNA target [81] (Figure 6). RISC is a multiple turnover enzyme; the siRNA guide
strand incorporated localizes the RISC complex to the RNA target, the target is cleaved and
the RISC complex is released intact and able to start a new round of cleavage [33, 76, 82].
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Figure 6: Chemical mechanism of RISC-catalysed target-mRNA cleavage
The RISC catalyses a phosphodiester hydrolysis reaction that generates 3´ -hydroxyl and 5´ -
phosphate termini. The scissile bond is shown in red (modified from E. Sontheimer [79]).
The first position of a small RNA in RISC does not contribute to binding, as was first noted
in studies designed to predict miRNA targets [83, 84]. Instead, bases 2-8 form a 5´ end of
anti-sense strand (a “seed”) that are important to pair with target candidate sequences. It
was proposed that bases 2-8 of several miRNA were complementary to conserved sequence
elements in the 3´ untranslated regions (UTRs) of post-transcriptionally repressed mRNAs
in flies [85]. It is now clear that most of the binding energy that tethers RISC to a target
RNA comes from bases in the 5´ half of the small RNA complementary to mRNA [46, 82].
This is a key difference between siRNA or miRNA and antisense oligonucleotides, where
all bases contribute equally to specificity. In fact, complete pairing of the 3´ half of an
miRNA or siRNA to its target RNA is not required for translational repression, provided
that multiple small RNAs are bound to the target [46], nor for target mRNA destruction.
This could mean that most active siRNAs will not only down-regulate their intended mRNA
targets, but also could reduce expression of other mRNAs possessing partial complementary
to the siRNA guide strand [86].
                                                                                    
2. 2. 4. Other silencing models
In the translational repression pathway, small RNAs direct RISC to bind mRNA and repress
its translation into protein, rather than cleaving it. Animal miRNAs typically mediate
translational repression. In contrast, most plant miRNAs direct target cleavage. In all of the
Mg2+ Mg2+
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well-studied examples of translational repression by animal miRNAs or siRNAs,
translational repression is a response to the binding of multiple small RNA-programmed
RISC complexes to the sites in the 3´ UTR of the mRNA target. The presence of multiple
potential recognition sites in 3´ UTR sequences is a useful predictor of an mRNA for being
regulated by miRNA [84]. The degree of complementarity between a small RNA and its
RNA target helps to determine if the small RNA directs target cleavage or represses mRNA
translation, because an A-form helix must be formed with the target RNA at the centre of an
siRNA guide strand for cleavage to occur [82, 87]. In the absence of such a helix,
translational repression occurs. Translational repression occurs at some step after
translational initiation, since the distribution of ribosomes along the repressed mRNA is
indistinguishable from the same mRNA undergoing active translation [45]. Ketting and
Plasterk [88] propose that RISC somehow directs degradation of the nascent polypeptide,
rather than simply stalling translational elongation. Both models are currently without
experimental support. A recent evidence demonstrated that RISC complex guided by
miRNA, brings the target mRNA in specialised cytoplasmic structures called P-bodies
where the mRNA is degraded by the cellular RNA nucleases [89-91].
Small RNAs can also direct the formation of heterochromatin. The only complex thus far
established for this pathway is the S. pompe RITS, a RISC-like complex that contains
siRNA, an Argonaute protein (Ago1), the chromodomain protein Chp1, and Tas3, a protein
of unknown function [54, 55]. How the RITS directs modification of histones to promote
formation of heterochromatin is unknown. It is not known if the RITS binds the DNA of the
targeted gene or binds nuclear RNA transcribed from targeted DNA sequences. dsRNA
targeting promoter sequences also triggers transcriptional silencing in plants [92]. siRNA-
directed transcriptional silencing via DNA metthylation was recently reported in animals
[49].
2. 3.  Lentiviral transgenesis
For the past two decades, pronuclear injection of DNA has been the most widely used
method for generating transgenic mice. The cloned DNA is microinjected directly into the
pronucleus of fertilized embryos. An important advantage of pronuclear injection is that it is
not limited to certain species; it works nicely in mice and also has been used to produce
transgenic farm animals like pigs. However, this technique has a low efficiency of
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transgenesis. In mice, the transgene is integrated and expressed in not more than 4% of the
animals generated from injected oocytes [93]. Because the production of transgenic mice by
DNA microinjection is standardized, the losses during the injection is compensated by high-
throughput production and screening.
The first viral transgenesis in mammals was done three decades ago. Janisch and Mintz
employed a simian virus to transfer genetic material into mouse embryos [94].
Subsequently, Jaenisch reported the successful germ line integration of retroviral DNA in
mice and its transmission into their offspring [95]. Later, other groups tried to replace viral
genes by mammalian DNA in the virus to express it ectopically in animals. However, the
genes cloned into these integrated retroviruses were not expressed in newborn mice. This
block was not restricted to rodents, but it was also observed in cattle [96]. This
transcriptional repression is thought to be mediated by both cis-acting de novo methylation
of the integrated provirus and by cell-type-specific trans-acting transcriptional repressors. In
addition, the major disadvantage of simple retroviral vectors is their inability to transduce
non-dividing cells, which renders them extremely inefficient as an in vivo gene delivery
system. In contrast with retroviruses, lentiviruses have the ability to infect also non-dividing
cells [97, 98], because the lentiviral genome is actively transported into the nucleus [99,
100].
2. 3. 1.  Lentiviruses
Lentiviruses belong to the large family of retroviruses [101]. The genus lentiviradea
includes the human immunodeficiency viruses HIV-1 and HIV-2; the simian
immunodeficiency virus, SIV; and nonprimate lentiviruses, such as the visna virus, equine
infectious anemia virus (EIAV), feline and bovine immunodeficiency viruses (FIV and
BIV) and some others. The mechanism by which lentiviruses infect non-dividing cells has
not been completely elucidated. However, several studies have indicated that, by using the
host cellular nuclear-import machinery, the gag, vpr and pol gene products can mediate an
active transfer of HIV-1 pre-integration complexes into nuclei of non-dividing cells [102,
103]. In addition, lentiviruses carry at least three other genes, such as tat and rev, that
contribute to the more complex life cycle of lentiviruses. After entry into the host cell, the
viral RNA genome is reverse transcribed into DNA, which is integrated into the host
genome (provirus) and serves as a template for production of progeny (virions). The
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integration into the host cell genome is the basis for persistent infection and transmission of
the integrated provirus to offspring after infection of germ cells (vertical transmission).
2. 3. 2.  Lentiviral gene transfer vectors
Novel lentiviral vectors have been shown to work in many different settings, where gene
transfer is needed, but was not achieved with vectors based on retroviruses [104]. The first
lentiviral vectors were derived from HIV-1. Nowadays, an advanced third generation of
HIV-based vector systems is available. Similar transfer vectors were developed from other
lentiviruses [105, 106]. For reasons of biological safety, the typical lentiviral vector system
carries the necessary minimal information for the formation of infectious particles is
distributed on separate vectors and packaging cells. The transgene of interest is inserted
between the LTRs.
2. 3. 3.  Self-inactivating vectors
An important safety concern with lentiviral vectors was the possibility of insertional
mutagenesis and activation of cellular proto-oncogenes. Thus, lentiviral vectors were
designed in a way that viral regulatory elements within LTRs required for replication were
deleted. The resulting vectors are known as self-inactivating (SIN) allowing the formation
of infectious but non-replication competent viral particles [107]. It was also hoped that the
SIN vectors may escape gene silencing, because it was assumed that active viral promoter
sequences might recruit the host cellular silencing machinery to the integrated provirus.
Because the viral promoters were removed in the SIN vectors, other promoters had to be
introduced to drive transgene expression. Most of the lentiviral vectors designed till now
contain ubiquitously expressing promoters that allow broad transgene expression in almost
all organs. Such promoters are the human cytomegalovirus immediate early promoter
(CMV) [98], the promoter of the human phosphoglycerate kinase gene (PGK) [108], the
human ubiquitin-C promoter [109] and the GAG promoter (a chicken beta-actin/CMV-
compound promoter) [110]. By introduction of regulatable transcriptional elements, spatial
and temporal regulation of the lentiviral transgene expression can be achieved. Nowadays,
the most frequently used regulatable system is the bacterial tetracycline (Tet) resistance
system.
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2. 3. 4.  Vector elements
A feature of lentiviral vectors is the incorporation of a Rev-responsive element (RRE) that
enhances the production of unspliced vector RNA in the packaging cells. Thus, even
complex transgenes containing introns and splicing signals can be included into the vector.
Incorporation of a central DNA flap, the polypurine tract (cPPT) of the pol gene, is another
important cis acting factor. The cPPT enhances the import of the HIV-1 pre-integration
complex into the nucleus of the infected cells [108].
The viral transduction efficiency was further enhanced by the posttranscriptional regulatory
element of woodchuck hepatitis virus (WPRE) [111]. Insertion of the WPRE in the 3´
untranslated region of lentiviral vectors enhances transgene expression 5- to 8 fold in a
promoter- and transgene-independent manner [111].
2. 3. 5.  The lentiviral packaging system
The vectors carrying the above mentionned genes do not contain the lentiviral packing
system. Therefore, the viral proteins gag and pol required for the production of lentiviral
particles are provided in trans by packaging/producer cells. The Rev protein is also
expressed in the packing cells to achieve sufficient expression of unspliced vector RNA and
of the gag and pol genes, which carry RREs [112].
The env gene, which determines the tropism of retro and lentiviruses, has to be provided to
obtain infectious particles. Similar to simple retroviruses, the tropism of lentiviral vectors
can be changed by replacing the wild-type env gene with the envelope gene of another virus
(Pseudotyping). The lentiviruses currently used are pseudotyped with the G protein of
vesiculostomatitis virus (VSV-G) [104]. The advantages of these pseudotyped viruses
(VSV-G) are the broad host range of VSV and the stabilization of the particles that can be
concentrated by ultracentrifugation [104].
2. 3. 6.  Generation of transgenic animals by using lentiviruses
A breakthrough for virus-mediated transgenesis was the switch in use of simple retroviruses
to lentiviruses [109, 110]. Several groups introduced foreign genes into murine
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preimplantation embryos at the zygote and morula stage using SIN vectors, generating
transgenic mice. The transgene was expressed and further passed to the offspring (F1-
generation) through the germ line. The F1 mice exhibited also transgene expression. By
using different promoters, ubiquitous as well as tissue-specific expression was achieved
[109]. In addition, different ways of infection were tested. The zona pellucida is a physical
barrier that protects embryos from lentiviral infection. Therefore, either the zona pelucida
has to be removed (denudation) or the virus has to be delivered into the perivitelline space
by injection (subzonal injection). The draw back of the denudation was delayed embryonic
development and reduced implantation rates [109]. Subzonal injection of the lentivirus was
less invasive than DNA microinjection. Comparison between DNA microinjection and
lentiviral transgenesis revealed a more than 8-fold increase in the number of transgens
incorporated per embryo. If one considers only F1 progeny, lentiviral transgenesis was 4
fold more efficient than DNA microinjection.
Another way to generate transgenic mice by lentiviral infection is gene transfer into
embryonic stem (ES) cells. Similar to the situation in preimplantation embryos, lentiviral
vectors proved to be superior to retroviral vectors in infecting ES cells. Lentivirally-infected
murine ES cells expressed the transgene during in vitro [113] and in vivo differentiation
[110]. Injection of lentivirus-infected ES cells into blastocysts, followed by embryo transfer
into fosters, resulted in the birth of chimeric animals that expressed the transgene in all cells
derived from the transduced ES cells [110]. Embryos derived from crossing of chimeric
mice expressed the transgene, indicating successful germ-line transmission.
The DNA microinjection is the most widely used technique for the production of transgenic
mice. However, in farm animals the problem of low efficiencies is more pressing, because
of the high production costs. Therefore, Hofmann [114] used a lentivirus that carries the
gene encoding green fluorescent protein (GFP) to infect zygotes of pigs. The viral particles
were injected into the subzonal space between the cytoplasmic membrane and zona
pellucida. Subzonal injection had no significant effect on embryonic development. A
transfer of 244 lentivirus-infected porcine embryos into six recipient pigs resulted in the
birth of 46 piglets. The advantage of using GFP as the reporter lies in the easy identification
of transgenic progeny. Of the piglets born, 32 (13% of the infected embryos) carried the
transgene and 30 expressed it. In comparison to DNA microinjection, lentiviral transgenesis
resulted in 27-fold higher yield in transgenic animals expressing the transgene per treated
embryo. In all of the tissue analysed, including derivatives of three primary germ layers:
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ectoderm (skin), endoderm (gut) and mesoderm (cardiac muscle), GFP was expressed.
Furthermore, by incorporation of human keratin K14 promoter, Hofmann et al. were able to
direct transgene expression exclusively to the skin of the pigs. They also showed that the
transgene is present in germ line cells, which is the basis for its transmission to offspring.
Initial experiments using retroviral vectors resulted in a dramatic increase in transgenesis
rates in cattle [96], however, retroviral transgenesis in cattle did not meet the high
expectations [115]. The first experiments using lentiviruses to infect preimplantation
embryos were not successful. By switching to lentiviral infection of bovine oocytes before
in vitro fertilization, Hofmann et al. [116] generated lentiviral transgenic calves. All of the
calves were transgenic and 100% of these animals expressed ubiquitously eGFP as detected
by in vivo imaging and Western blotting.
The development of an efficient method for genetic modification of chickens had significant
technical difficulties [117]. The earliest methods developed were based on the use of avian
retroviruses and replication-defective vectors derived from reticuloendotheliosis virus
[118]. Recently, an ALV replication-defective vector was used to produce transgenic birds
at low frequency, probably because of host silencing of the viral sequences. Michael
J.McGrew [119] investigated the efficiency with which lentiviral vectors could transduce
the chicken germ line and examined the expression of introduced reporter transgenes. Ten
founder cockerels transmitted the vector to between 4% and 45% of their offspring and
stable transmission to the G2 generation was demonstrated. Analysis of expression of the
reporter gene constructs in several transgenic lines showed a conserved expression profile
between individuals that was maintained after the germ line transmission. These data
showed that lentiviral vectors can be used to generate transgenic birds with an about 100-
fold higher efficiency than with any previously published method, with no detectable
silencing of transgene expression between generations.
For many applications in immunology, toxicology and cardiovascular research, the rat
provides a more attractive model than the mouse. In addition, there several good rat models
available for studding major human diseases such as hypertension, diabetes and multiple
sclerosis. Unfortunately, the classical approach to generate transgenic rats by pronuclear
injection is technically challenging. Therefore, the development of lentiviral vectors
provided an attractive alternative to this technique. Janes van den Brandt et al [120]
generated eGFP-transgenic rats using the lentiviral approach. Analysis of the founder
generation demonstrated that 46% of the offspring had stably integrated the provirus into
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the genome and of those 92% expressed eGFP in all blood-derived leukocytes. In contrast
to their offspring, all founder rats were mosaic with regard to eGFP expression. The
expression level of eGFP in the F1 generation is influenced by the site of proviral
integration. A single copy of the transgene is sufficient for reliable detection by flow
cytometry, irrespective of the leukocyte subtype. Adoptive transfer of purified CD4+ T-
lymphocytes from transgenic rats and next re-isolation from various organs demonstrated
that expression of the lentiviral transgene is maintained in a foreign host and allows for
efficient tracking of transferred cells.
2. 3. 7.  Induction of RNAi in transgenic mice generated by the use of lentiviral vectors
RNAi is a post-transcriptional regulatory mechanism of gene expression which occurs, in a
broad variety of eukaryotic organisms, as described above [16]. It also was recognized as an
antiviral defence process that protects organisms from RNA viruses [17]. The development
of siRNA expression systems that are based on transcription of short hairpin RNAs from
expression plasmids containing Type III RNA polymerase (Pol III) promoters, such as the
U6 [121] and H1 [122] RNA promoters, has broadened the use of RNAi dramatically.
Lentiviral vectors carring an U6-driven siRNA was recently shown to induce efficient gene
silencing in mice [123]. Infection of CD8-positive T cells with a lentiviral vector carrying
siRNA directed against CD8 resulted in a more than 90% reduction of CD8 expression,
showing the efficacy of lentiviral siRNA delivery. Infection of ES cells with such a RNAi
lentivirus resulted in chimeric mice that exhibited 89% reduction in expression of target
protein (CD8). Direct infection of single-cell embryos resulted in transgenic mice with a 88-
94% decrease in CD8 expression in the F0-generation [123]. In addition, infection of GFP-
transgenic zygotes with lentiviruses resulted in the suppression of GFP expression in the
double-transgenic animals [124]. In another paper, Wange Lu et al. [125] succeeded to
silence the Ryk receptor in transgenic mice expressing siRNA against it by a lentiviral
vector system. The founder mice were mosaic but most of F1 animals died after birth, with
survivors displaying a Ryk knockdown by 90%, defects in axon guidance and reduced body
size in comparison to wt littermates.
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2. 3. 8.  Aim of the project
The goal of the project was to generate HNF4γ knockdown mice using a lentiviral vector
system for expression of siRNA against the mRNA of that nuclear receptor. We hoped to
achieve ubiquitous high expression of the U6/shRNA expression cassette. This knockdown
approach to investigate gene function in vivo by using lentiviral transgenesis was considered
as an attractive alternative to the classical knockouts. It was hoped to allow the production
of a sufficient number of transgenic founder (F0) animals with a high degree of transgenesis
within three months permitting functional and expression analysis of the targeted gene
avoiding further breeding of the F0 animals. This method would be an ideal way for a quick
gain of biological data. As the siRNA technology is quite new, a major issue was to
determine the efficiency of transgenesis as well as to compare transgene expression and the
dependence of gene knockdown from the sequence of the shRNA selected. As a model for
in vivo knockdown I have chosen the hepatocyte nuclear receptor 4 γ (HNF4γ) for which no
knockout mouse exists. HNF4γ is a member of the nuclear receptor family, and until
recently it was considered as an orphan receptor. It is highly homologous to HNF4α;
however its chromosomal localization is distinct and knowledge about its expression pattern
and function is scarce. Therefore expression analysis was done, and the knockdown of this
gene was performed in the hope to shed light on its role in development and physiology.
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3. Results
3. 1.   Analysis of HNF4γ expression
Since HNF4γ is a newly discovered nuclear receptor and since only limited information on
its expression was available, I first looked by conventional RT-PCR which organs express
HNF4γ. As seen in Figure 7 expression of HNF4γ gene is restricted to kidney, liver,
intestine, pancreas and colon (Figure 7).
Figure 7: Expression analysis of HNF4γ mRNA by conventional RT-PCR
RT-PCR was performed on cDNA prepared from different organs: left to right; (1) liver, (2) kidney,
(3) brain, (4) intestines, (5) skin, (6) muscle, (7) thymus, (8) pancreas, (9) lung, (10) spleen, (11)
colon
The conventional RT-PCR is a semi-quantitative method and it does not allow a precise
determination of the level of gene expression. Therefore, I performed quantitative real-time
PCR. It has a sensitivity at least five orders of magnitude better than the best blotting
procedures and a dynamic range of more than 10 orders of magnitude. This unsurpassable
sensitivity and range has allowed to develop PCR into a powerful quantitative tool [126-
128]. In a PCR reaction in principle the amount of a target DNA-template is doubled with
every cycle, so ideally the reaction can be described by the exponential function y=y0 2
n
where y  is the quantity of target sequence at cycle n  and 0y  is the initial quantity of
template (Figure 8). But due to the fact that in a realistic PCR not every template is
replicated in every cycle, a PCR is better described by the equation y=y0 E
n where E  is the
so called efficiency of the reaction. The maximum efficiency E  possible in PCR is 2 –
β actin
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Figure 8: Three imaginary curves of PCR reactions obtained
by plotting the quantity of product against the cycle
numbers. The PCR reactions start with initial template
amounts y0, y0’ and y0” and so reach after N, N’ and N”
number of cycles the set detection threshold Y.
every PCR product is replicated every cycle. The minimum value is 1, corresponding to no
amplification. For quantification a certain detection threshold, Y  is set and depending on
the starting amount of template and the efficiency of the reaction it needs a specific number
of cycles N  to reach this threshold (Figure 8).
NEyY 0= .
The intersection of this detection threshold and the amplification curve represents the
crossing point. The real-time PCR analysis for HNF4γ showed high mRNA levels in
intestine and much lower level of expression in kidney, liver and pancreas (Figure 9).
Figure 9: Quantitative HNF4γ
analysis performed by real-time
PCR
Real-time PCR reveals highest levels
of HNF4γ in intestine and low level
of expression in liver and kidney.
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The lining of small intestine is a single-layered epithelium which covers the surface of the
villi that project into the lumen, and it lines the crypts that descend into the underlying
connective tissue. Dividing stem cells lie in the depths of the crypts. They generate four
types of differentiated cells (1) absorptive cells (brush-border cells), with densely-packed
microvilli on their surfaces to increase active surface area; (2) goblet cells, secreting mucus;
(3) Paneth cells, forming part of the innate immune system; and (4) enteroendocrine cells
secreting serotonin and peptide hormones that regulate the growth, proliferation and
digestive activities of cells of the gut and other tissues. The absorptive cells travel upward
from the stem-cell region and within 2-5 days they reach the tips of the villi, where they
undergo initial stages of apoptosis and are finally discarded into the gut lumen.
In adult mouse intestine HNF4γ protein is restricted to mature brush-border cells of the villi.
In comparison to the related HNF4α, HNF4γ cannot be seen in crypts (Figure 10).
         villi
      crypt
Figure 10: Expression of HNF4γ and HNF4α proteins in adult mouse intestine.
Immunohistochemical analysis reveals overlapping and distinct expression patterns of HNF4γ (left)
and HNF4α (right) in adult mouse intestine.
HNF4γ showed differential expression along the gut with maximum levels in proximal
intestine (duodenum) and low expression in colon (4 times less; data not shown). No
HNF4γ transcript was detected in stomach.
During embryogenesis the gut derives from the endoderm. To identify whether HNF4γ
expression occurs already in the developing intestine I performed immunohistochemical
HNF4αHNF4γ
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analysis of intestinal tissue from day E16.5. The HNF4γ protein was detectable in the
mature cells (brush-border cells) of the villi (Figure 11).
Figure 11: HNF4γ expression in the intestine of E16.5 mouse embryo.
Immunohistochemical analysis performed by a HNF4γ -specific antibody shows HNF4γ protein
accumulation in enterocytes of villi (arrows).
The pancreas is the second organ where HNF4γ protein was detected. Pancreas is separated
in exocrine and endocrine tissue. The exocrine pancreas is the bigger part which accounts
for more than 99% of its mass. It consists of the cells that secrete bicarbonate to neutralize
the acidity coming from the stomach and other cells that secrete digestive enzymes that
work at neutral pH. The endocrine pancreas is represented by so called islands of
Langerhans randomly distributed within exocrine tissue. The islands of Langerhans are built
of β-cells secreting insulin (80% of the island cells), α-cells secreting glucagon and δ-cells
with other functions. The immunohistochemical analysis demonstrated HNF4γ protein only
in the islands (Figure 12). Because of the low sensitivity of the HNF4γ antibody it was not
possible to determine in which cells HNF4γ protein is expressed.    
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Figure 12: HNF4γ protein in the islands of Langerhans
Immunohistochemical analysis shows HNF4γ protein present in the islands of Langerhans.
3. 2.  Selection of effective shRNA molecules against HNF4γ
Criteria for efficient siRNA based on thermodynamics have been determined allowing
prediction for siRNA efficiency. For this purpose I used the published program Sirna stored
on the Sfold server which website is freely available [129]. The program Sirna combines the
most recent algorithms based on thermodynamics together with algorithms underlying RNA
target accessibility. Based on this software I selected five oligonucleotides which I cloned
into the mouse U6 promoter in the context of pBluescript II KS (+/-) backbone (Figure 13).
The resulting constructs (pU6-shRNAs) can form a shuttle system allowing easy re-cloning
of the whole U6-shRNA cassette into the pLentiLox 3.7 vector. The shRNA-615 was
modified at position 18 of the sense strand from T to C in order to destroy a stop sequence
for RNA polymerase III (Figure 14). The hairpin shRNA-615 will have an imperfect match
between C and A at that position which could make this particular shRNA more efficient
than what the Sirna program predicts, due to destabilization of the 5´-end of the antisense
strand of mature siRNA. The shRNA-303 has a low score (score 7) and was selected as a
non-functional shRNA against HNF4γ.
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Figure 13: The sequence predicted by the Sirna program and efficiency of different shRNA
hairpins against HNF4γ
The sense and antisense sequences of shRNA molecules selected by the Sirna program: (1) total
score for siRNA dupex; (2) target accessibility score; (3) duplex feature score; (4) duplex
thermodynamics score; (5) siRNA GC content; (6) antisense siRNA binding energy (kcal/mol); (7)
differential stability of siRNA duplex ends (DSSE, in kcal/mol); (8) average internal stability at the
cleavage site (AIS, in kcal/mol); (9) total stability of siRNA duplex (kcal/mol).
615-  633  GUGAGGUCUUGCCAGAUUUTT AAAUCUGGCAAGACCUCACTT  AA
              9  1   7  1  47.4%   -3.0    5.1   -9.2  -38.8
  303-  321  GUCAACUGUUUAUGUGCCATT UGGCACAUAAACAGUUGACTT  GU
              7  0   6  1  42.1%    0.1   -2.2   -7.4  -36.9
1320- 1338  GAUCCACUAACUGGGCAAATT UUUGCCCAGUUAGUGGAUCTT  AA
             12  5   5  2  47.4%  -11.0    3.0   -8.2  -39.4
1301- 1319  GCACCCACAUUUAUCUCAATT UUGAGAUAAAUGUGGGUGCTT  AU
             14  5   8  1  42.1%  -10.3    4.6   -9.4  -37.2
655-  673  GCACUGACAUAAAUAUUAATT UUAAUAUUUAUGUCAGUGCTT  CA
             15  4   9  2  26.3%   -9.0    6.7   -8.2  -30.7
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shRNA-1320
shRNA-303
shRNA-1301
shRNA-655
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Figure 14: shRNA-615 modification
Predicted structure of shRNA-615 with the modification of the base at position 18 in the sense
strand.
Since shRNA adds additional complexity in comparison to siRNA, as the processing
enzyme Dicer  is involved [130-132], I used the GeneEraser Luciferase Suppression-Test
System (Stratagene) to test the candidate shRNA sequences. In this assay system, the
sequences to be targeted by shRNA expression are inserted in the 3´ UTR of a luciferase
gene. Following luciferase activity allowed selection of the most potent shRNA sequences.
The vectors expressing shRNA (pU6-shRNA) were co-transfected into HEK293 cells at
various amounts with the luciferase/HNF4γ fusion construct and an additional vector
expressing Renilla luciferase serving as transfection control. Two days after transfection,
expression of the luciferase was determined by measurement of luciferase activity (Figure
15).
Figure 15: Analysis of knockdown efficiency of shRNA sequences against HNF4γ by the
GeneEraser Luciferase Suppression-Test System
The test was performed with 5 different shRNAs in a titration experiment: orange 100ng shRNA;
yellow 10ng shRNA; green 1ng shRNA; dark green 100pg shRNA.
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All U6-shRNA constructs showed dose-dependent silencing of the HNF4γ target sequence.
By chance, four of the five shRNA performed equally well with a slight preference
observed for shRNA-1301 and shRNA-655. This was in good agreement with the Sirna
program prediction, since these two oligonucleotides have the highest total scores (15 and
14 respectively). The construct shRNA-303 with a total score 7 performed worst. According
to the Sirna software, the sense strand (passenger strand) of the mature siRNA-303 should
be incorporated preferentially in the RISC complex leading to an inefficient knockdown.
3. 3.  Generation of transgenic mice using LentiLox 3.7
For the generation of HNF4γ knockdown mice I used the pLentiLox 3.7 vector to generate a
lentiviral vector system that expresses shRNA synthesized from the U6 promoter [123].
This system is a third generation lentiviral system that contains a mutated 3´ LTR providing
high biological safety (Figure 16).
Figure 16: The LentiLox 3.7 vector system
The LentiLox 3.7 virus contains a CMV-driven EGFP reporter gene and an U6-based shRNA
expression cassette.
The pLL 3.7 vector also contains a CMV-driven EGFP reporter gene the expression of
which should allow to follow transgene transmission in mice. The U6-shRNA cassette was
excised from the pU6-shRNA expression plasmids and cloned into the pLL 3.7 lentiviral
vector.
To compare the efficiency of the knockdown in mice with the cellular assays in vitro, all
five U6-shRNA expression cassettes were introduced into the pLentiLox 3.7 vector.
Infectious virus particles were produced in 293HEK cells and concentrated by
sin-LTRWREsin-LTR
Ψ cPPT U6 CMV EGFP
sense antisense
terminator
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ultracentrifugation to approximately 0,5-4 x109 infectious units/ml. Approximately 10 to
100pl of the concentrated virus particles were injected into the perivitelline space of mouse
embryos at the 1-cell stage. After 24h, embryos were implanted into pseudo-pregnant foster
mothers. To estimate efficiency of the lentiviral infection, embryos from the 4-cell stage
and developmental day E3.5 were collected and analysed by confocal microscopy. The
results showed mosaic expression of the reporter EGFP gene (Figure 17).
Figure 17. Differential expression of the reporter EGFP gene of the LentiLox 3.7 vector
system.
The EGFP differential expression revealed by confocal microscopy from 4-cell embryos: The
pictures were taken consecutively beginning from the top (1) and proceeding to the middle of the
embryo (26). Note that one of the cells has a weaker EGFP expression.
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The mosaic expression of the EGFP gene was even more obvious in the blastocyst stage
where the cells from the ICM (inner cell mass) showed different green signals (Figure 18).
Figure 17. Mosaic expression of the lentiviral reporter EGFP gene in the ICM of early
embryos.
The confocal microscopy from embryos E3.5 reveals mosaic expression of the reporter EGFP
transgene in the cells from ICM. The pictures were taken consecutively beginning from the top (1)
and proceeding to the bottom of the embryo (29).
From 1184 embryos transferred 206 founder mice (F0) were born. 117 F0 mice (56%) were
positive for provirus integration as tested by tail PCR (Table 1), but only 52 founders
showed visible, but mosaic EGFP expression in skin.
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Constructs Zygote
transfers
F0
pups
born
PCR-
positive
F0
PCR
positiveF0,
back
crossed
F0 with
germ line
transmission/F0
giving green F1
F1
pups
yielded
PCR-
positive F1
Green
F1
shRNA-615 156 20 14 11 3/1 125 8 2
shRNA-1320 224 29 24 14 12/0 125 39 0
shRNA-303 150 27 19 1 1/0 18 9 0
shRNA-1301 350 45 27 12 6/2 122 31 7
shRNA-655 304 85 33 14 8/5 163 45 24
total 1184 206 117 52 30/8 553 132 33
Table 1: Embryo viability, germ line transmission and transgene expression in mice
generated by recombinant LL3.7 virus
The table presents the number of zygotes transferred, the yield of PCR positive and PCR negative
founders and F1 mice, and the number of EGFP-expressing mice.
3. 3. 1.  Copy number and segregation of the transgene
Southern blot analysis of F0 mice demonstrated the presence of multiple independent
integration events ranging from 1 to 10 copies. The band intensity, however, varied,
pointing to genetic mosaicism (Figure 19).
Figure 19: Transgene copy number and mosaicism in F0 mice generated by recombinant
LL3.7 virus
Southern blot analysis of tail DNA prepared from founder mice reveals multiple virus integration
events and mosaicism.
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Mice that showed detectable spots of EGFP expression in skin were mated to C57Bl/6 wild
type mice to generate a F1 progeny. 30 out of 52 founders transmitted the transgene as
evidenced by PCR, but only 8 of those 30 founders gave rise to EGFP-positive F1 mice
(Table1). Of 553 F1 mice, 421 were PCR- negative. Only 132 mice were positive by PCR,
and of these only 33 mice expressed EGFP (Table 1). These EGFP-positive F1 mice had
distinct integration sites, as evidenced by Southern blot analysis, and showed different
levels of EGFP expression. The bands corresponding to the pro-viral integration sites were
characteristic for each founder and segregated among the progeny (Figure 20).
 Figure 20: Segregation of the transgene among the F1 progeny
Southern blot analysis of founder C (left) and founder D (right) and transgene segregation in the F1
progeny.
 3. 3. 2.  Transgene expression in LentiLox 3.7 F1 mice
We next asked whether the EGFP reporter is ubiquitously expressed in the EGFP-positive
F1 mice as expected from the properties of the CMV promoter. Therefore I analyzed EGFP
fluorescence in F1 mice bred from two different founders (founder A and founder B) by
inspection of the skin as well as by analysis of sections prepared from different organs.
F0-C F1-1 F1-2 F0-D F1-1 F1-2 F1-3
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Figure 21: Copy number, segregation and site-dependent expression of the EGFP in
transgenic F1 mice derived from founder A
Southern blot analysis of tail DNA prepared from founder A and segregation in F1. The level of
EGFP expression was different between different F1 mice, depending of the site of provirus
integration.
The founder A gave birth to two kinds of offspring named A-I and A-II, which had distinct
provirus integration sites and in which a different extent of EGFP expression as observed by
skin fluorescence (Figure 21). Some of the insertions found in tail DNA of the founders
were not transmitted through the germ line. The A-I mice showed ubiquitous EGFP
fluorescence (but with a weak signal in liver and spleen), but expression was variable with
the strongest signals in skin, pancreas, intestines, muscle, kidney and heart (Figure 22).
F1mice
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Figure 22: Tissue sections of organs from the A-I mouse
EGFP visualization of organ sections from F1 A-I mice; (1) brain, (2) kidney, (3) heart, (4) liver, (5)
intestine, (6) pancreas.
In F1 A-II mice, EGFP was predominantly expressed in pancreas, heart, liver, kidney, but in
general the EGFP signal was weaker (except the liver) than in A-I animals (Figure 23).
Figure 23: Tissue sections of organs from the A-II mouse
 EGFP signal in organ sections from F1 A-II mice; (1) brain, (2) kidney, (3) heart, (4) liver, (5)
intestines, (6) pancreas.
The founder B generated  two different F1 mice (B-I and B-II), but in contrast to F1-A mice
only B-I showed EGFP fluorescence in the skin (Figure 24).
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                                                              F1 mice
Figure 24: Copy number, segregation and integration site-dependent expression of the EGFP
transgene in F1 mice derived from founder B
Southern blot analysis of tail DNA prepared from founder B and segregation of the transgene among
the progeny. The EGFP expression is apparent only in B-I mice.
In the analysis of F1 B-I mice an EGFP signal was observed only in pancreas and in some
cells of the base of intestinal crypts (Figure 25).
Figure 25: Sections
of pancreas (1-2)
and intestines (3-4)
from B-I mice.
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To answer the question whether EGFP expression correlated with the amount of shRNA
transcribed from the U6 expression cassette, I performed Northern blot hybridization of
total RNA isolated from intestine, pancreas (mice B-I and B-II) and from intestine,
pancreas, liver, heart, kidney and brain (mice A-I and A-II) with 32P-end labelled sense
oligonucleotide probes.
Northern blot of F1-B mice showed the presence of mature siRNA in pancreas and small
intestine with the highest levels in pancreas. Mice positive for virus integration, but without
an EGFP signal (B-II), never showed detectable levels of siRNA transcribed from the
transgenic U6 promoter although the signal from the endogenous U6 gene is clearly
detectable (Figure 26).
Figure 26: Correlation between EGFP and siRNA expression in lentivirus-positive F1-B
mice
Northern blot hybridization for monitoring of siRNA expression with total RNA isolated from
pancreas and intestine of F1-B mice (B-I, B-II and wild type control). The blot was re-hybridized
with a 32P-labelled U6 RNA oligonucleotide probe.
F1 mice (A-I and A-II) bred from founder A expressed mature siRNA. Mice A-I had a
stronger siRNA signal in heart, intestine, brain, kidney and pancreas compared to A-II and
undetectable siRNA in liver, correlating with EGFP expression as shown in Figure 22.
Again, the signal of transgenic siRNA was weaker in comparison to the endogenous U6
gene (Figure 27).
U6
siRNA
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Figure 27: Correlation between EGFP and siRNA expression in lentivirus positive F1-A
mice
Northern blot hybridization for monitoring of siRNA expression using total RNA isolated from
different organs of mice A-I and A-II. The blot was re-hybridized with a 32P-labelled U6 RNA
oligonucleotide probe.
3. 3. 3.  Knockdown of HNF4γ by lentiviral siRNA
As shown above, HNF4γ is expressed predominantly in the differentiated, absorptive brush
border cells of the small intestine (enterocytes) and to a lower degree in the islets of
Langerhans of the pancreas (Figure 11). To address the question whether HNF4γ  is
knocked-down in mice expressing siRNA directed against HNF4γ (A-I, A-II, B-I) the level
of its messenger RNA was measured by qPCR in the two target tissues of transgenic mice
and its wild type littermates. The F1 A-I, A-II and B-I mice (expressing shRNA-1301 and
shRNA-655) showed a knock down of HNF4γ by 80% in pancreas and of about 50% in
intestine (Figure 27).
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Figure 28: In vivo knockdown of HNF4γ gene expression
Knockdown measured by quantitative real-time PCR; (a) pancreas (A-I, A-II and B-I F1 mice) (b)
intestine of A-I mice.
Only in the intestine of A-I mice a knockdown of about 50% was detectable (Figure. 29),
but not in A-II and B-I animals.
Figure 29: A knockdown of HNF4γ in the intestines of A-I mice
Immunohistochemical analysis demonstrated a reduced level of HNF4γ in the intestine of A-I mice.
The physiological role of HNF4γ is unknown. HNF4γ is highly related to nuclear receptor
HNF4α, abundantly expressed in liver, kidney, intestine and to a lower degree in the islets
of Langerhans in pancreas. A recent analysis of mice with a β cell-specific inactivation of
HNF4α showed impaired glucose homeostasis in these animals [133].
To test the possibility that HNF4γ is also involved in regulation of glucose metabolism I
performed a glucose tolerance test using A-I mice, which had an 80% HNF4γ knockdown in
pancreas and wild type littermates as control (Figure 30).
WT MUT
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Figure 30: Glucose tolerance test using HNF4γ knockdown and wild type control mice
Since no significant difference in the glucose tolerance test was seen between HNF4γ
knockdown and wild type mice, we have so far no evidence that HNF4γ is involved in
glucose homeostasis.
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4.  Discussion
A new methodology for generation of transgenic mice using lentivirus-based vectors was
employed to produce a knockdown of HNF4γ gene.
I have analyzed the expression pattern of HNF4γ gene, the transgenesis by the lentiviral
vector LL 3.7 that expresses EGFP under control of the CMV promoter as reporter and
different shRNA sequences directed against HNF4γ under control of the U6 promoter, the
rate of germ line transmission, and transgene expression in founder and F1 mice.
4.1. Tissue distribution and expression of the HNF4γ gene
Since HNF4 γ is a recently discovered member of the nuclear receptor family I first wished
to determine its tissue distribution. My analysis demonstrated that expression of HNF4γ is
restricted to intestine and pancreas. Traces of mRNA were found also in liver and kidney at
very low levels. Interestingly, in intestine HNF4γ showed a highly selective pattern of
expression as it was detected only in the nuclei of brush-border cells (enterocytes). These
cells are the most abundant, but short-lived cell population of intestine villi. After they exit
from the crypt and migrate toward the tip of the villus they initiate a genetic program, which
allows absorption of nutrients and water. A comparison with the closely related
transcription factor HNF4α in intestine showed that this gene is expressed in both crypt and
villus cells. Recently it was demonstrated that both nuclear receptors can bind the same
hormone responsive elements on apoA-I/C-III/A-IV gene cluster [10] suggesting
overlapping functions. Since, HNF4γ protein is found exclusively in the villi this suggested
that HNF4γ and HNF4α might have separate functions. Mobility shift assays with nuclear
extracts prepared from mouse intestinal villi identified HNF4γ as a nuclear receptor which
is capable of binding to a new HRE found in the distal promoter of apoA-IV, thereby
restricting the expression of apoA-IV gene only to enterocytes [10]. It is possible that the
spatial expression of many gut-specific genes may be controlled by the HNF4γ/HNF4α
ratio within crypt-to-villus axis in vivo. HNF4γ protein is already detectable in the embryo
at day E16.5 suggesting for a potential role of this nuclear receptor in intestine development
from the embryonic endoderm. Immunohistochemical analysis performed on pancreatic
tissue demonstrated expression of HNF4γ protein in the cells of Langerhans islands.
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Since there was no described knockout of HNF4γ, the knockdown approach to investigate
gene function in vivo by using lentiviral transgenesis was considered as alternative
possibility. The generation of knockout mice is time consuming and requires intensive
breedings. Therefore there was the hope that lentiviral based transgenesis would allow the
production of a sufficient number of highly transgenic founder mice. As the siRNA
technology is a new tool it brings some uncertainty about the efficiency of the DNA
constructs designed for the HNF4γ knockdown. It was therefore desirable to select shRNA
sequences in vitro to reduce the number of mice to be generated.
4. 2. Selection of effective shRNA oligonucleotides against HNF4γ
For knockdown experiments in vivo it is highly desirable to first identify siRNA and shRNA
sequences that are most effective in suppressing target gene expression. In principal, several
siRNA/shRNA sequences can be chosen to attenuate expression of a given target gene. On
the basis of the relatively small number of target genes that were successfully silenced, a set
of empirical guidelines have been proposed for the design of siRNA [75] (Figure 5). One of
them includes low stability of the 5´antisense terminus that promotes incorporation of the
antisense strand (AS) into the RISC complex. A high stability of the 5´ RNA sense strand is
required to prevent sense strand incorporation. Low stability of siRNA in the middle might
facilitate the cleavage of passenger strand and to increase the processing rate of the RISC
machinery [72]. Consistent with these criteria several softwares were designed in a way to
predict the knockdown efficiency of candidate siRNA oligonucleotides [134-136]. The
more advanced of them have an additional capacity to measure the thermodynamic stability
around the target site as well as secondary structure of mRNA. Recent data on mRNA target
accessibility demonstrated that the relative instability of mRNA around the siRNA target
site represented as loops and mismatches was beneficial in achieving successful
knockdown. Nevertheless, such software could be useful in the design of siRNA sequences
that can be tested in cell culture experiments, but not with full confidence for shRNA,
preferable species for stable knockdown in vivo. ShRNAs are more complex structures that
resemble endogenous miRNA harbouring loop and stem sequences. Both miRNA and
shRNA are transcribed by either RNA polymerase II (Pol II) or by Pol III, processed by
Drosha/Pasha heterodimer and then transported to the cytoplasm by Exportin-5. In the
cytoplasma shRNAs and miRNAs additionally are cleaved by the Dicer enzyme to generate
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a mature siRNA which is incorporated into the RISC complex and guide the degradation of
target mRNA (Figure 31).
Figure 31: Key steps in miRNA biogenesis
The pri-miRNA are transcribed by RNA polymerase II and processed by the Drosha/Pasha
(DGCR8) heterodimer to pre-miRNA. Then pre-miRNAs are transported to the cytoplasm where
they undergo additional cleavage by the Dicer enzyme leading to mature miRNA. The shRNA are
transcripts which resemble pre-miRNA in structure and biogenesis, but are expression products of
exogenous DNA constructs bearing either Pol II or Pol III promoter. (Modified from B. Cullen ).
Because of this structural complexity of shRNA and its downstream processing steps the
use of computer programs for predicting to which extent a given shRNA will be efficient in
achieving desirable knockdown is quite challenging. A preliminary experimental test for the
efficiency of shRNA including panel of different shRNA is therefore highly desirable. For
my experiments, I used the commercially available GeneEraser Luciferase Suppression-Test
Sytem (Stratagene). In this system, the target DNA sequence is cloned within the 3´UTR of
luciferase gene. By co-transfection of this construct with constructs expressing shRNA
molecules it should be possible to select functional shRNA sequences. Efficiency was
determined in a titration experiment. By a careful design including varying amounts of the
plasmids it is possible to keep different vector-to-vector molar ratios. Moreover, if the
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molar concentration for all tested pU6-shRNA constructs is the same, the state of the
balance between shRNA and mRNA expression will be dependent only on the shRNA
efficiency. A second advantage of the experimental test over the computer program is that
available computer softwares do not consider changes in the shRNA such as mismatches,
whereas the impact of this kind of modification on shRNA efficiency can be directly
measured experimentally. For example shRNA-615 has a total score of 9, the estimation
done by the Sirna program predicting either an inactive or at least a less active
oligonucleotide. However, the substitution U to C at position 18 possibly avoided the stop
signal for Pol III and improved the knockdown efficiency of the hairpin. In the case of
shRNA-303, the performance shown by this oligonucleotide in cell culture experiment
correlated well with predictions of the program. This molecule was selected as a
negative/inefficient hairpin by the Sirna program and was used as reliability control in the
test assay. The other shRNAs against HNF4γ achieved a nice knockdown in the test
experiment and this result was consisted with the Sirna score prediction.  One disadvantage
of the test luciferase assay is that it is performed by co-transfection of several plasmids in
cells (293T) that naturally do not express the HNF4γ target gene. This situation implicates
an uncertainty about the knockdown efficiency in the mouse. A solution for such an
obstacle will be that pre-selection of shRNAs either is done in a cell line expressing the
endogenous target (if such a line is available) or is done using a construct allowing more
cell-type independent shRNA-based knockdown. Unfortunately, I could not evaluate the
shRNA potency in vivo and compare with the results obtained in the in vitro cell culture,
because the number of mice expressing the shRNA was too low. It also turned out that
siRNA expression was also dependent on the integration site, a confounding complication
that was not considered when the work was started.
4. 3. Generation of transgenic mice using the LentiLox 3.7 lentiviral
system
4. 3. 1 Analysis of F0 mice
To generate transgenic mice, LentiLox 3.7 lentiviral high titer preparations of 0,5-4 x 109
infection units/ml were microinjected within the perivitelline space of the zygote resulting
in 56% of F0 mice carrying the transgene as determined by PCR. This number is rather high
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in comparison to DNA incorporation after plasmid nuclear injection (4-5%). One possible
reason is that the delivery of the transgenes by LL 3.7 lentivirus is less invasive resulting to
better survival of the embryos. The LL 3.7 is a self-inactivating, replication-defective, third
generation of lentiviruses which is pseudotyped with the G-protein of the vesiculostomatitis
virus (VSV-G) [101]. This pseudotyping allows the virus to infect a broad range of cell
types from diverse species. There is no need of mechanical delivery by needle of the
provirus particles through the cell and nuclear membranes and thus increasing the chance
that more embryos will not be injured and will continue to develop further in the next stage.
Southern blot analyses of tail DNA from F0 mice showed 1 to 10 individual integration
events and this number most likely is dependent on the virus titer applied. The variable
intensity of some Southern bands indicated that F0 mice were genetically mosaic as it was
already seen by EGFP expression in the skin in living animals or in other organs after
dissection (data not shown). Only 52 founders of 117 (44%) showed a spotted EGFP
expression on the skin (data not shown). An explanation for the high degree of mosaicism
could be that integration of the virus into the host genome may take place only after the
zygote has completed several rounds of divisions, thereby only a subset of the embryonic
cells become transgenic [120] (Figure 32). This delay in lentivirus genome integration could
be based on the nature of the lentiviruses themselves. These viruses have RNA as a
molecule bearing the whole genetic information. Once the virus has entered the cell, its
RNA is used as a template to generate complementary DNA chain (cDNA) which then is
converted to double-strand DNA. The double-strand DNA forms a pre-integration complex
together with the protein products of gag, vpr and pol genes, and this complex moves within
the nucleus of the host cell. The virus enzyme integrase catalyzes integration of the
invading virus DNA in the genome (provirus) that later serves as a template for progeny
production (virions). The DNA integration also is the basis for transgene transmission to the
progeny after germ cell infection.
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Figure 32: Mosaic expression of EGFP transgene in 8-cell stage mouse embryo
Confocal microscope picture revealed mosaicism in early embryo infected by LentiLox 3.7 virus.
The infection possibly takes place after zygote makes several rounds of division.
Another reason for the mosaicism observed in F0 mice may be transgene silencing during
embryo development. This argument comes from the fact that the majority of the F0 mice
were positive for the lentiviral integration, but never expressed EGFP transgene. The
transgenesis by lentiviruses was shown to escape epigenetic DNA modification in contrast
to transgenesis mediated by retroviruses [110]. Recent data showed a high preference of
murine leukaemia virus (MLV) and HIV-based vectors for integration into genes expressed
actively[137, 138]. Our observations on embryo development in vitro demonstrated that
indeed in most embryos at the morula stage EGFP was expressed at high level indicating
lentivirus integration and expression, whereas at the more advanced blastocyste stage the
EGFP expression either disappeared completely or became mosaic with respect of
localization as well as of strength of expression. Specifically, only few cells within the inner
cell mass still showed EGFP expression (Figure 17). This switch off of the EGFP reporter
might coincide with the switch off of the early embryonic genes where the virus was
integrated in. Because of the localization of the transgene within these genes, EGFP reporter
and shRNA expression are strongly influenced by the silencing mechanism at that particular
chromosomal place.
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Figure 33: Efficiency of the infection by LentiLox 3.7 virus
The figure shows the total number of infected embryos, percentage of surviving founder mice and
percentage of PCR+ founder mice.
The high degree of mosaicism seen in the founder mice (F0) was a disappointing
observation, since we wished to analyze these animals without the need to breed further to
produce the next generation.
In order to decrease the genetic mosaicism of F0 mice and make them useful for in vivo
experiments a change in the protocol was tried. The zygotes were denuded by removal of
the zona pelucida of the egg that could serve as a physical barrier to the lentivirus. The
denuded embryos were incubated in high titer preparations of LentiLox in the hope that the
opened surface of the mouse egg leads to uniform exposure of the embryonal cells and
increased numbers of lentiviruses bound to the cell membrane, and consequently higher
uptake. Our experience showed that denudation did not harm viability of the embryos and
that they continue to develop normally (data not shown). However, this technique did not
contribute to a decrease of mosaicism (data not shown). A possible explanation could be
that irrespective of the higher chance to increase the virus number within the egg, all of the
viruses will need again the same time for the formation of the pre-integration complex as
well as for the DNA integration. As an alternative, a method that could delay the embryo
development for example by reducing the incubation temperature may help lentivirus
biogenesis. A new lentiviral vector that will carry a selectable marker gene will allow the
implanted infected zygotes: 1184
surviving founders:  206
PCR-positive founders: 117
founders with green signal: 52
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embryo to develop under a selective pressure. In these conditions only those embryonic
cells will survive that express the selective marker in parallel with shRNA cassette. In an
ideal case these cells will proliferate further contributing to the whole embryo with reduced
expression of the target gene.
4. 3. 2 Analysis of F1 mice
The 52 EGFP-positive F0 mice were further mated with C57Bl/6 mice to determine the
extent of germ line transmission. From 48 crosses, 553 F1 mice were generated (Figure 34).
30 mice F0 transmitted the transgene in the germ line. A minor fraction of F1 mice were
transgenic with 2 or more integrations (132/24%) and showed transgene segregation as
found by Southern blot (Figures 20, 21 and 24). This low degree of germ line transmission is
correlated with the high degree of mosaicism seen in the founder mice.
Figure 34: Low rate of germ line transmission due to mosaicism of F0 mice
The figure shows the number of F0 mice backcrossed, with and without germ line transmission, and
the frequency of generated F1 animals.
Founders backcrossed : 52
EGFP positive F1
F0 with germline transmission:30
F0 without germ line
transmission: 22
green F1: 33non green transgenic F1: 99non transgenic F1: 421
=  25%
=  23.9%total F1: 553
= 5,9%
EGFP negative F1
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An additional unexpected result was that only 25% (33) of the PCR-positive F1 mice
expressed EGFP, and even in EGFP-positive F1 mice EGFP expression was not ubiquitous,
indicating for epigenetic effects (silencing) during development, provirus integration into
heterochromatin or into genes with low expression.
However, it was found that EGFP (CMV-dependent) and siRNA (Pol III-dependent)
expression was highly correlated. Both promoters used are known to be active in all or
almost all cells. The strong EGFP expression correlated with a similarly strong siRNA
expression and vice versa (Figure 26 and 27). The expression pattern of both was
quantitatively variable in the different F1 lines analyzed and in some lines tissue- and cell
type-dependent. For example, F1 mice from the B-I line expressed EGFP in crypt cells of
the intestine (Figure 25) and as was expected never showed knockdown of HNF4γ gene
which expression is characteristic for enterocytes localized in the villi. A-I mice showed
ubiquitous EGFP and siRNA expression and HNF4γ in both pancreas and intestine was
attenuated. Interestingly, the expression of siRNA in all F1 mice was weaker than the
expression of endogenous small U6 gene as evidenced by Northern blot (Figure 26 and 27).
Since, both endogenous U6 and shRNA are driven by the same PolIII/U6 promoter one
should expect the same or at least a similar level of expression. It is possible that lentivirus
integration took place at a chromosomal site that does not fully support the expression of
shRNA, because of either the lack of important enhancers or presence of silencing DNA
elements.  With the exception of the sequences coding for different shRNA, the integrated
vector was identical allowing the conclusion that transgene expression (siRNA and EGFP)
is most likely dependent on the integration site. If this finding can be extended to other
lentiviral vector systems it would strongly limit the use of lentiviral vectors as gene shuttles.
As an experimental alternative, transgenic knockdown mice might be produced by using the
BAC (bacterial artificial chromosome) technology. BACs are big DNA molecules that
contain certain genes together with all their regulatory elements (promoter and enhancers).
Therefore, by placing a shRNA cassette within the open reading frame of a given gene it
would be possible to achieve a tissue and cell type knockdown effect. Since the BACs are
huge molecules they can also allow site-independent expression of siRNA.
Recently it was also demonstrated that introduction of a single copy of shRNA cassette into
appropriate genomic locus by homologous recombination in ES cells can lead to strong
decrease in expression of the target gene [139].
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4. 4. In vivo knockdown of HNF4γ gene expression
Among 10 green F1 mice analyzed a knockdown of HNF4γ levels in pancreas and intestine
were found. The knockdown in intestine was 50%, which may lead to the lack of
phenotype. The knockdown in pancreas was more pronounced (80%). Giving the fact that
HNF4γ is highly related to HNF4α we asked for a role of HNF4γ in regulation of glucose
metabolism. However, the results obtained from glucose tolerance tests showed no
significant difference between the knockdown and control mice. A possible explanation
could be that the reduced protein level of HNF4γ in pancreas is compensated by the
induction of some alternative biochemical pathways regulated by other transcription factors
from the same group.
4. 5. Conclusions
The use of the LentiLox 3.7 lentiviral delivery system [123] for the production of HNF4γ
knockdown mice resulted in founder mice that were genetically mosaic and therefore not
suitable for analysis without further breeding. The high degree of mosaicism was reflected
in a low rate of germ line transmission. The number of transgene-positive F1 mice
expressing EGFP and siRNA was unexpectedly low (6% of the total F1 number) despite of
several provirus integrations. The low number of F1 expressing EGFP and shRNA is most
likely due to epigenetic silencing during embryo development as well as integration site-
dependent silencing, arguing that the lentiviral vector system used given its low efficiency
is not suitable to replace conventional transgenesis by microinjection of DNA into the pro-
nucleus.
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5.  Materials and Methods
5. 1.  Equipment
PCR thermocyclers (MJ Research), LightCycler (Roche), heating blocks (Eppendorf),
centrifuges and microcentrifuges (Heraeus, Sorvall, Megafuge, Beckman), fluorescent
microscope (Nikon), digital cameras (Sony, Visitron Systems), binoculars (Nikon, Leica),
cell counter (CASY1, Schärfe System), hybridization oven (Stuart Scientific), scintillation
counter (Beckman), thermostat incubators (Labotect, Mytrom, Aqualytic),
spectrophotometer (Beckman), luminometer (Luminoskan Ascent, Labsystems), power
supplies (BioRad, Consort), gel UV photo documentation system (Biostar), electroporator
(BioRad), waterbaths (GFL, Grant), UV crosslinker (Stratagene), micropipettes (Gilson),
multi-channel pipettes, vortexes, agarose gel and PAGE minigel chambers, microwave
oven, shakers, rotators, homogenizers.
5. 2.  Materials
Reagents and consumables were bought from Stratagene, Bio-Rad, Boehringer Mannheim,
Eppendorf, Falcon, Fluka, Invitrogen, Amersham, Sigma, Roche, Roth, Whatmann and
others:
Agar; Agarose; Ampicillin; Blocking Reagent; Swine serum; Chloroform;
Diethylpyrocarbonate (DEPC); Dithiothreitol (DTT); dNTPs; EDTA; EGTA; Ethanol;
Ethidiumbromide; Formamide; G50 Microcolums; Glycerol; HEPES;
Hydrochloric acid; Hydrogen peroxide; Isoamyl alcohol; Isopropanol; Kanamicin;
Luciferin; Lysolecithin; Magnesium chloride; Methanol; Mineral oil; Nitrocellulose
membrane; Nonidet P-40 (NP-40); Paraformaldehyde (PFA); Phenol; Potassium chloride;
Proteinase K; SDS; Sodium acetate; Sodium chloride; Sodium hydroxide; Spermidine
trihydrochloride; Spermine tetrahydrochloride; ß-Mercaptoethanol (ß-ME); Triton X-100;
TRIZOL Reagent; Sucrose; Trypsin; Tween-20; X-ray film; Yeast tRNA
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5. 3.  Enzymes
Enzymes were bought from:
Restriction enzymes                                      Roche Molecular Biochemicals, Mannheim (D)
                                                                      New England Biolabs, Schwalbach (D)
                                                                      Promega, Mannheim (D)
Klenow- Fragment                                        Roche Molecular Biochemicals, Mannheim (D)
Alkaline Phosphatase                                    Roche Molecular Biochemicals, Mannheim (D)
T4-DNA-Ligase                                            Roche Molecular Biochemicals, Mannheim (D)
T4-Polynucleotide kinase                              Roche Molecular Biochemicals, Mannheim (D)
Pfu-DNA-Polymerase                                   Promega, Mannheim (D)
RNAse A                                                       Qiagen, Hilden (D)
Proteinase K                                                  Roth, Karlsruhe (D)
5. 4.  Radioactivity
(α-32P)dCTP (3000 Ci/mmol, 10mCi/ml), Fa. Amersham
(γ-32P)ATP (3000 Ci/mmol, 10mCi/ml), Fa, Amersham
5. 5.  Special kits
QIAprep spin mini-prep kit (Qiagen)
QIAGEN Plasmid Midi, Maxi
QIAex gel extraction kit  (Qiagen)
QIAquick PCR purification kit  (Qiagen)
RneasyR Mini Kit (50) (Qiagen)
SuperScriptTM First-Strand Synthesis System (Invitrogen)
Mm00660262_g1 (Hmbs) TaqMan Gene Expression Assay (Applied Biosystems)
Mm00443563_m1 (HNF4γ) TaqMan Gene Expression Assay (Applied Biosystems)
Platinum Quantitative PCR SuperMix-UDG (Invitrogen)
GeneEraserTM Luciferase Suppression-Test System (Stratagene)
Dual Luciferase Reporter Assay kit  (Promega)
VECTASTAIN ABC peroxidase system (Vector laboratories)
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5. 6.  Plasmids
pBluescriptII SK (Stratagene)
phRL-TK (Promega)
pTarget-luc (Stratagene)
pU6-shRNA plasmids (pBluescriptII SK based)
pd2EGFP (Clontech)
LentiLox 3.7 (pLL3.7) (Van Parijs Laboratory)
5. 7.  Competent E. coli strains
XL-1 Blue
DH 10β (Invitrogen)
TOP 10 (Invitrogen)
XL10-Gold : Deficient in all known restriction systems. The strain is endonuclease-
deficient (endA), and recombination deficient (recA). The Hte phenotype increases the
transformation efficiency.
 5. 8.  Mouse strains
-C57BL/6 mice were obtained from CR Wiga, Germany
5. 9.  Buffers and solutions
5. 9. 1.  Isolation and storage of DNA
TE-buffer pH 8 (for plasmid-DNA)
10mM Tris/HCL pH 8.0
1mM EDTA, pH 8.0
TE-buffer pH 7.4 (for genomic DNA)
10mMTris/HCL pH 7.4
1mM EDTA, pH 8.0
5. 9. 2.  Buffers for the alkaline lyses of bacteria and plasmid preparation
Buffer P1 (Resuspention buffer)       100 µg/ml RNAse A
                                                           50 mM Tris/HCL pH 8.0
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                                                           10mM EDTA pH 8.0
Buffer P2 (Lysis buffer)                     200 mM NaOH
                                                           1% SDS
Buffer P3                                           3 M Potassiumacetate pH 5.5
5. 9. 3.  Buffers for genomic DNA preparations
NID Buffer                                        KCl 50mM
                                                          Tris Hcl pH 8.3 10 mM
                                                          MgCl2 2mM
                                                          Gelatine 0,1 mg/mL
                                                          NP 40  0,45%
                                                          Tween 20  0,45%
Tail Buffer                                        Tris HCl 50 mM
                                                          EDTA 100 mM
                                                          NaCl 100 mM
                                                          SDS 20%
5. 9. 4.  Buffers for DNA electrophoresis
50x Tris-Acetate Buffer (TAE)        2M Tris
                                                          250 mM Na-Acetat
                                                          50 mM  EDTA pH 8
6x Probe Buffer                                0,25% Bromphenol blue
                                                          0,25% Xylene cyanol FF
                                                          15% Ficoll 400
                                                          in H2O
DNA Ladder
Smart Ladder (Stratagene)               5µl per line
5. 9. 5.  Medium for culturing of bacteria
LB (Luria/Bertani)                         10g/l Trypton
                                                        5g/l Yeast extract
                                                        5g/l NaCl
                                                        pH 7.0 with NaOH autoclaved
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5. 9. 6.  Medium for culturing of 293T cells
DMEM                                           10%FCS
                                                       1xGln (1:100 dilution)
                                                       1x HEPES (1:100 dilution)
5. 10.  Standard Molecular Biological Techniques
5. 10. 1. Plasmid Mini-prep DNA preparation
1) Grow the bacteria in 2 ml LB medium overnight.
2) Pellet the bacteria at 5000 rpm, remove the supernatant and dissolve the bacteria in
250µl buffer P1.
3) Add 250µl of buffer P2 and mix by inversion and incubation for 5 minutes at room
temperature.
4) Add 250µl  buffer P3, mix and incubate on ice for 5 minutes.
5) Clear the supernatant by two rounds of centrifugation at 13,000 rpm for 5 minutes in
a tabletop centrifuge. Each time transfer the supernatant to a new tube.
6) Precipitate DNA by adding 750µl isopropanol and centrifugation for 10 minutes at
13,000 rpm.
7) Wash the pellet by 70% ethanol, dry it and dissolve it in 50µl TE buffer.
5. 10. 2.  Genomic DNA preparation
5. 10. 2. 1.  DNA preparation for Southern blot
To achieve good results from Southern blot, at least 10-20 µg DNA are needed.
1) Cut 0,5 cm from the mouse tail and transfer it in Eppendorf tube.
2) Add 700 ml of tail buffer supplemented with 10 µl Proteinase K (10mg/ml).
3) Incubate over night at 560 C.
4) Mix gently and add 260 µl saturated 6 M NaCl. Mix on Eppendorf mixer.
5) Centrifuge at 13,000 rpm for 10 minutes.
6) Transfer the supernatant in a new Eppendorf tube and add the same volume
phenol:chlorophorm (1:1) and shake gently on Eppendorf mixer for 2-3 minutes.
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7) Centrifuge at 13,000 rpm for 10 minutes.
8) Transfer the supernatant in a new Eppendorf tube and add 0,7 volumes isopropanol.
Mix the solution gently.
9) Centrifuge at 13,000 for 10 minutes.
10) Wash the DNA pellet with 500µl 70% ethanol.
11) Dry the DNA pellet for 5 minutes at room temperature and dissolve it in appropriate
volume TE buffer.
12) Measure the concentration of the DNA.
5. 10. 2. 2.  DNA preparation for genotyping by PCR
The DNA for PCR was prepared using short protocol with NID buffer.
1) Cut small piece of the mouse tail and transfer it in Eppendorf tube with NID buffer
and Proteinase K (2-3µl of 10mg/ml).
2) Incubate the tails over night.
3) Shake solutions for 5 minutes on Eppendorf mixer and incubate them at 950 C
shortly to inactivate Proteinase K.
4) Use 2µl of the tail solution for PCR.
5. 10. 3.  DNA electrophoresis
0,6-2% agarose gels were used for the analysis of DNA fragments of 0,1-7 kb size. The gels
were prepared using 1x TAE buffer containing 1µg/ml ethidium bromide; 1x TAE was used
as a running buffer. Electrophoresis were performed at constant voltage for 30-60 minutes,
and the DNA bands were visualised using UV-Transilluminator.
5. 10. 4.  Southern blot
1) After the digest with an appropriate enzyme run the DNA electrophoresis on low
voltage for 6 hours at least.
2) Stop the electrophoresis and expose the gel on UV-Transilluminator to confirm nice
digestion of the genomic DNA and document the picture.
3) Incubate the gel by shaking in 0,25 N  HCl for 10 minutes.
4) Incubate the gel in 0,4 N NaOH two times each for 20 minutes (denaturation).
5) Incubate the gel in 20x SSC for 5 minutes.
6) Build the blot;
MATERIALS AND METHODS
_________________________________________________________________________
56
Turn the gel up side-down on glass with bridges over 10x SSC buffer . Put the Biodyne
B Transfere Membrane (Pall) onto the gel tightly and mound 6 rows of Whatman paper.
Add additional paper and press for over night.
7) Dismantle the blot. Wash the membrane with 2x SSC for 15 minutes and crosslink it
under UV illumination(1200 mJ/cm2).
8) Pre-hybridise the membrane with church-Gilbert buffer (0,5M NaHPO4 pH 7.2; 7%
SDS; 1mM EDTA pH 8.0) for at least 1 hour at 650 C.
9) Incubate the membrane in church buffer with the radioactive probe over night at 650
C.
10) Wash the membrane first with Wash buffer I (40mM NaHPO4 pH 7.2; 1mM EDTA
pH 8.0; 5% SDS) and then with Wash buffer II (0,5M NaHPO4 pH 7.2; 1mM EDTA
pH 8.0; 1% SDS).
11) Dry shortly the membrane between paper lists and put it in cassette with Phospho-
imager screen.
12) Incubate for 5-6 hours and document the signal.
5. 10. 5.  Random labelling of probes for Southern blot
For the random labelling of the probe a Klenow enzyme was used.
1) Dilute the template DNA 2µl (DNA probe 200ng) in 11µl H2O.
2) Incubate on 950 C for 5 minutes and then transfer the tube immediately on ice for 5
minutes.
3) Add Klenow enzyme (1U/µl)
4) Add (α-32P) dCTP 5µl
5) Add 5µl mix of dNTPs without dCTP (5x OLB mix).
6) Mix gently and incubate for three hours at 370 C.
7) Purify the labelled probe using G-50 columns following the manufactures
instructions (Amersham).
8) Measure the efficiency of the probe labelling by calculating the ratio CPM
probe/CPM total.
5. 10. 6.  Preparation of electro-competent E.coli cells
All the steps should be done as cold as possible, always on ice! The glass pipettes should be
cooled once or twice by pipetting cold 10% glycerol up and down before pipetting cells.
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1) Pick single colony from DH 10β, XL1 blue or TOP 10 E. coli bacterial cells and
grow them in 50 ml LB medium without antibiotic.
2) Transfer 2 ml culture in new 50 ml LB medium and grow bacteria for additional 3
hours.
3) When the cells reach log phase (OD600= 0,4-0,5) pour into 50 ml falcon tubes and
cool down on ice for 15 minutes.
4) Cool down the rotor for 10 minutes at 00 C by centrifuging at 4,000 rpm.
5) Spin the cells for 10 minutes at 4,000 rpm at 00 C.
6) Aspirate the supernatant and immediately put on ice, re-suspend cells in 50 ml of ice
cold 10% glycerol. Repeat washing 2 times with 10% glycerol.
7) Pour away the supernatant and dry the tube on ice with Kleenex tissue.
8) Re-suspend the cells in the remained liquid (around 250µl).
9) Transfer 50µl of the cells into each pre-cooled Eppendorf tube and freeze in liquid
N2 or use directly for electroporation.
 5. 10. 7.  Immunohistochemistry protocol (cryo sections)
1) Sacrifice the mouse.
2) Take out the tissue of interest and cut it to small pieces (intestine).
3) Put the pieces intestine immediately in 50ml Falcon tube with 4% PFA/PBS.
4) Rotate the Falcon tube with the intestine for12 hours at 40 C.
5) Wash 1 time in PBS to remove remained drops of PFA.
6) Incubate the tissue in the same tube with 30% sucrose for 12 hours at 40 C.
7) Wash ones with PBS.
8) Embed the tissue in Tissue -tec and freeze it on dry ice.
9) Make the 5-7 microns thick sections on cryostat.
10) Store the sections at – 200 C or proceed according to the protocol.
11) Post-fix the sections into 4%PFA/PBS for 10 minutes on ice.
12) Wash 3 times for 5min each in PBS.
13) Cook the sections in citrate buffer (10x stock solution)
                   2 minutes  maximum power
                  10 minutes 180 W
14) Cool down at RT for 30 min.
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15) Wash with PBS for 5 minutes.
16) Incubate the sections in 1%H2O2 for 15-30 minutes (8,3ml 30% H2O2 + 125ml
PBS,125ml MeOH).
17) Wash three times in PBS.
18) Surround the sections by Pad-pen.
19) Drop 40-50µl 5% NSS.
20) Incubate 30 min under humid conditions.
21) Aspirate the NSS and incubate with the first Ab in proper dilution (For HNF4g 1:500).
22) Leave the sections under humid conditions at 40 C for 12 hours.
23) Wash 3 times in PBS.
24) Drop the secondary Ab for 30 minutes (1:500 for HNF4γ and 1:900 for HNF4α dilution
in PBS).
25) Wash 3 times in PBS.
26) Incubate with ABC (peroxidase) for 30 min.
27) Wash 3 times in PBS.
28) Perform staining reaction for several minutes.
29) Cover the sections and look them under a microscope.
VECTASTAIN ABC peroxidase system (Vector laboratories) 100µL A + 100µL B into
10ml PBS
Staining: Tris-Trizma; 0,74g/100ml H2O; 40mg 3,3´ -diaminobenzidine (SIGMA) (DAB);
25µl  30%H2O2
5. 10. 8. Restriction analyses
To set up restriction reaction use 1U restriction enzyme per 1µg DNA.
Reagents Amount
Restriction buffer (10x) 5µl
Rstriction enzyme 1U 1µl
DNA (1µg) 1µl
H2O 13µl
Incubation time 1 hour at 370 C
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5. 10. 9.  Dephosphorylation of 5´ ends of dsDNA to prevent self-annealing of vector
Reagents Protruding ends Blunt ends
DNA 1 pmol 0,2 pmol
10x Dephosphorilation buffer 2 µl 2µl
Shrimp Alkaline Phosphatase 1U 1U
H2O Add up to 20µl Add up to 20µl
Incubation 1 hour at 37 C 2 hours at 37 C
To stop, the reaction can be incubated for 15 minutes at 650 C.
5. 10. 10. Ligation of DNA fragments
Sticky ends:
If vector DNA and insert DNA are similar in length, a molar ratio of 1:3 (vector versus
insert DNA) is recommended.
If vector and insert DNA are not similar in length, a molar ratio of 1:1 or 1:2 (vector versus
insert DNA) is recommended.
Blunt ends: a molar ratio of vector DNA to insert DNA of 1:5 is recommended.
Reagents Sticky ends Blunt ends
DNA Up to 1µg digested DNA Up to 1µg digested DNA
10x ligation buffer 3µl 3µl
T4 DNA ligase 1-5 U 1-5 U
H2O Add up to 30µl Add up to 30µl
Incubation 200 C for three hours 200 C for three hours
5. 10. 11. PCR
Reagents Amount
10mM PCR Nucleotide Mix
(each dNTP 200µM)
1µl
Upstream and downstream primer 0,1-
0,6 µM each
1µl
Template DNA 0,1-0,25 µg variable
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H2O variable
Volume 25µl
The program for PCR is depends on the running application.
5. 11.  Selection of effective shRNA molecules against HNF4γ
The selection of shRNA molecules against HNF4γ is described in section “Results”.
5. 12.  Oligonucleotide Design
For the cloning of shRNA against HNF4γ pU6-empty was digested by Hpa I and Xho I
restriction enzymes. The oligonucleotide design must incorporate a 5´ T in order to
reconstitute the –1 nucleotide of U6.
5. 12. 1.  Oligonucleotide format
Sense oligo: 5´ T-(GN18)-(TTCAAGAGA)-(18NC)-TTTTTTC
Antisense oligonucleotide: Complementary of the sense but with additional nucleotides at
5´ end to generate an Xho I overhang.
The loop sequence (TTCAAGAGA) is based upon Brummelkamp et al. [122].
The oligonucleotides were ordered from MWG and were purified.
5. 12. 2.  Cloning of the shRNA
5. 12. 2. 1.  Annealing Procedure
1) In a 1.5 sterile micro-centrifuge tube, set up the following annealing reaction at
room temperature. The final concentration of the oligonucleotide mixture is 50µM.
Reagent Amount
Top strand DNA oligo (500µM) 2µl
Bottom strand DNA oligo (500µM) 2µl
Annealing buffer:
100mM K-acetate; 30mM HEPES-KOH
pH 7.4; 2mM Mg-acetate
16µl
MATERIALS AND METHODS
_________________________________________________________________________
61
2) Incubate the reaction at 950 C for 4 minutes on heated block.
3) Switch off the block and leave the probes to cool down till room temperature. The
single-stranded oligonucleotides will anneal during this period.
4) Place the samples in a micro-centrifuge and centrifuge briefly (5 sec.).
5) Remove 1µl of the annealing mixture and dilute the ds oligonucleotides as described
in Diluting the ds oligonucleotides.
6) Store the remainder of the 50µM ds oligonucleotide mixture at –200 C.
5. 12. 2. 2.  Diluting of the ds oligonucleotides
         To clone ds-oligonucleotides into pU6-empty vector, the ds oligonucleotides must be
diluted and phosphorylated. The final concentration of the shRNA after phosphorylation
will be 10nM.
1) Dilute the 50µM ds-oligonucleotide mixture (from annealing procedure) 100-fold
into Dnase-free water (1µl of 50µM ds-oligonucleotide into 99µl of Dnase/Rnase-
free water) to obtain a final concentration of 500nM. Vortex to mix.
5. 12. 2. 3.  Phosphorylation of the ds-oligonucleotides
1) Set up the following reaction:
Reagent Amount
Phosphorylation buffer 10x 5µl
P o l y n u c l e o t i d e  Kinase
(10U/µl)
3µl
10mM ATP 5µl
ds oligo (500nM) 1µl
H2O 36µl
Total volume 50µ
Once the oligonucleotides are diluted, there should be three stocks of annealed ds-
oligonucleotides. Use each stock as follows:
-50µM ds-oligonucleotides (undiluted): Use this stock to prepare new diluted ds-
oligonucleotides if existing stocks become denatured or cross-contaminated.
-500nM ds-oligonucleotides (100 fold dilution): Use this stock for gel analysis.
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-10nM ds-oligonucleotides (5000-fold dilution): Use this stock for cloning.
5. 12. 2. 4.  Checking the integrity of the ds-oligonucleotides
When using the diluted ds-oligonucleotide stock solutions (100 or 5000-fold diluted stocks),
thaw the solutions on ice. Do not heat or allow the ds-oligonucleotide solutions to reach
greater than room temperature as this causes the ds oligonucleotides to melt. The
concentration of the oligos in the diluted solutions is not high enough to permit re-annealing
and instead favours the formation of intra-molecular hairpin structures. These hairpins will
not clone into pU6-empty vector.
 The integrity of the annealed ds-oligonucleotides was checked using agarose gel
electrophoresis.
5. 12. 2. 5.  Preparation of the pU6-empty vector for ligation
For the cloning of shRNA into pU6-empty, the vector must be opened by Hpa I and Xho I
enzymes in two separate restriction reactions. Usually a 10ng opened and dephosphorylated
vector for single cloning reaction is enough. For the set up of the restriction reaction look in
“Standard Molecular Biology techniques”.
5. 12. 2. 5. 1.  Digestion of pU6-empty vector by Hpa I and Xho I.
1)   Digest 10µg DNA with Hpa I.
2) Incubate the reaction at 370 C for over night.
3) Purify the vector after the digest using QIAquick PCR Purification Kit Protocol
Elute the Hpa I opened vector with 70µl EB buffer (Qiagen).
4) Set up the second digest by Xho I:
5) Incubate the reaction at 370 C for at least 6 hours.
6) Stop the reaction by putting it on the ice and prepare the 0.6-0.7% agarose gel.
7) Load the Xho I restriction reaction on the prepared gel and perform electrophoresis
on low voltage (100V-150mA) to purify the opened vector. A small DNA fragment
(30nt) will be released.
8) Extract the purified vector from the gel using the QIAquick Gel Extraction Kit
Protocol.
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9) Measure the concentration of the opened vector and perform analytical gel-
electrophoresis.
5. 12. 2. 6.  Dephosphorylation of the pU6-empty vector
To avoid vector selfligation a dephosphorylation of the opened pU6-empty vector is
recommended. The amount of the vector should be between 0,2 to 1 pmol. For the set up of
the dephosphorilation reaction look in “Standard Molecular Biology techniques”.
5. 12. 2. 7.  Cloning the shRNA ds-oligonucleotides into pU6-empty vector
For optimal results is recommended an approximately a 10:1 or 15:1 molar ratio of ds-
oligonucleotide insert: vector for ligation. The usual efficiency of the cloning should be
more than 90%. For the set up of the ligation reaction look in “Standard Molecular Biology
techniques”
5. 12. 2. 8.  Analysis of the clones after ligation reaction
To check for positive clones an analytical digest by Xba I (upstream of the U6 cassette) and
Xho I (downstream of the U6 cassette) should be performed. Digest 1µg plasmid with 1U of
each enzyme. For the set up of the restriction reaction look in “Standard Molecular Biology
techniques”.
1) Analyse the clones by gel-electrophoresis run on 2% agarose gel.
Figure 33: Analytical gel-electrophoresis of clones after cloning of shRNAs into pU6-
empty
The positive clones are represented by slightly bigger size of the released fragment: (m) DNA
Ladder; (1) negative control without shRNA cloned; (2-12) positive clones of pU6-shRNAs
      The positive clones are sequenced by MWG-Comfort read option.
m 1 2 3 4 5 6 7 8 9 10 11 12
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5. 13.  The GeneEraserTM Luciferase Suppression-Test System
The HNF4γ coding sequence was cloned into the 3` un-translated region (3`UTR) of the
luciferase gene. The 293T cells were transfected by the pTarget-luc-HNF4γ expression
vector and the plasmids encoding different shRNA molecules against HNF4γ gene. After
two days of culturing the luminescence of luciferase was measured. For better
discrimination of the knockdown effect of shRNAs against HNF4γ, a dose-dependence was
checked such that the concentration of pTarget-luc-HNFγ was kept constant  (5ng/well) and
that pU6-shRNA constructs were transfected in variable amounts (100ng/well; 10ng/well;
1ng;well; 100pg/well; 10pg/well; 1pg/well). For negative controls a pU6-empty and non-
related pU6-p53 were used. To achieve normalization for transfection efficiency and for
total DNA plasmid amount, the cells were also co-transfected with phRL-TK (expresses
Renilla luciferase) and pBluescriptII SK (up to 300ng DNA).  The experiment was
performed in triplicates using 96 well plate format.
5. 13. 1.  pTarget-luc Cloning Strategy
The target sequence was generated by digestion of construct containing the HNF4γ cDNA.
The product is incubated with the pre-digested pTarget-luc vector, Srf I and T4 DNA ligase.
Using the restriction enzyme in the ligation reaction (Srf I) is supposed to maintain a high-
steady-state concentration of digested vector DNA. If the target sequence contains Srf I
restriction site (5`-GCCCGGGC-3`), it will need to be mutated prior to clone into the
pTarget-luc vector.
5. 13. 2.  Releasing of HNF4γ cDNA sequence from pBK-CMV-HNF4γ expression
vector
The HNF4γ cDNA fragment was released by restriction digest of pBK-CMV-HNF4γ
expression vector by EcoR I and Xba I restriction enzymes. For the reaction were used
10µg DNA and 20U from each enzyme. For the set up of the restriction reaction look in
“Standard Molecular Biology techniques”.
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1) Stop the reaction by putting on the ice and load it on 0,6% agarose gel to perform
gel purification of the released HNF4γ cDNA sequence.
2) Gel-extraction of the HNF4γ coding sequence (QIAex gel extraction kit  (Qiagen)).
3)  Measure the concentration of HNF4γ cDNA fragment.
5. 13. 3.  Polishing the purified HNF4γ fragment
Since HNF4γ was generated by restriction, which leaves protruded 5´ ends on the fragment,
for successful cloning in the blunted pTarget-luc vector these ends have to be polished.
1) Set up the following reaction:
Reagent Amount
HNF4γ cDNA fragment 10µl
10mM dNTP mix (2,5mM
each)
1µl
Polishing buffer 10x 1,3µl
Pfu DNA polymerase (0,5U) 1µl
2) Mix the polishing reaction gently and add a 20µl mineral oil overlay.
3) Incubate the polishing reaction for 30 minutes at 720 C in a water bath.
4) Add an aliquot of the polishing HNF4γ fragment directly to the ligation reaction or
store at 40 C for future use.
5. 13. 4.  Cloning of HNF4γ  cDNA sequence into pTarget-luc pre-digested vector
For optimal results a correct insert to vector ratio must be considered. The following
equation suggested by Stratagene can be used:
X_ng of the fragment=(number of bp fragment)x(10ng of pTar-luc)/5695bp of pTarget
cloning vector. For HNF4γ with 2,2kb fragment the optimal amount is 350ng.
1) Set up the following reaction:
Reagents Amount
pTarget-luc cloning vector
(10ng/µl)
1µl
PCR-Script buffer 10x 1µl
rATP 10mM 0,5µl
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HNF4γ fragment 4µl
Srf I (5U/µl) 1µl
T4 DNA ligase (4U/µl) 1µl
H2O 1,5µl
2) Mix the ligation reaction gently and incubate for 1 hour at 250 C.
3) Store the ligation reaction on ice until ready to perform the transformation into the
XL10-Gold ultra-competent cells.
4) Transform the XL10-Gold ultra-competent cells according the manufacture
recommendations.
5. 13. 5.  Identifying Transformants Containing the HNF4γ insert
The presence and size of the target gene insert in the pTarget-luc vector may be determined
by PCR amplification of DNA from individual colonies. In addition, a second PCR with a
3´ target-gene specific primer will identify colonies containing pTarget-luc vectors with a
insert in the required sense orientation. Alternatively, the restriction digestion of isolated
plasmid DNA can be done to  determine the presence and orientation of the target gene.
5. 13. 5. 1.  A PCR strategy
For the PCR strategy, a single colonies after transformation can be picked by a small sterile
tip, and grow in 200µl LB media containing kanamicin for 4 hours. Use 2µl from the
culture media and set up the PCR reactions (colony PCR).
-Primers for Insert Amplification from the pTarget-luc Vector
Primer Nucleotide sequence (5´to 3´)
5´ primer GAAAGGTCTTACCGGAAAACTCGAC
3´ primer CAACAGATGGCTGGCAACTAGA
1) Set up the following PCR reaction as described in “Standard Molecular Biology
techniques”.
MATERIALS AND METHODS
_________________________________________________________________________
67
2) Gently mix each reaction and overlay with one drop of mineral oil.
3) Perform PCR using the following cycling parameters:
Number of
cycles
Temperature Length of time
1 cycle 950 C 1 minute
950 C 15 seconds
550 C 15 seconds
40 cycles
720 C 1 minute per kb
1 cycle 720 C 5 minutes
4) Analyse the PCR products on 1% agarose gel by electrophoresis. A PCR product of
160 bp is generated from the vector without an insert. The presence and orientation
of the target gene insert must be verified by nucleotide sequencing. The insert must
be in the sense orientation.
5. 13. 6.  Estimation of the efficiency of the different shRNA against HNF4γ
5. 13. 6. 1.  Transfection of 293T cells in 96 well plate format
1) The day before transfection, trypsinize and count the cells, plate them 2-6x104 cells
per well in 100µl of the appropriate complete growth medium without antibiotics.
2) For each well of cells, dilute 300ng of DNA into 25µl medium without serum (Opti-
MEM I Medium) in 96-well, sterile micro-titer plates.
3) For each well of cells, dilute 1µl of FuGENE 6 transfection reagent (Roche) into
25µl Opti-MEM I Medium and incubate 5 minutes at room temperature. Once the
FuGENE 6 is diluted, combine it with the DNA within 30 minutes.
4) Add 25µl of the diluted FuGENE 6 Reagent (from step 3) to each well containing
diluted DNA (from step 2), mix gently, and incubate at room temperature for 20 min
to allow DNA-FuGENE 6 Reagent complexes to form. The solution may appear
cloudy.
5) Add the DNA-FuGENE 6 Reagent complexes (50µl) directly to each well of the
plates containing cells and mix gently.
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5. 13. 6. 2.  Luciferase activity measurements and data processing
After transfection, the cells are cultured for 48 hours and then are subjected for lyses using
the reagents from Promega.
1) Dilute the passive lyses buffer 5 times freshly with distilled water in a container that
accommodates a multi-channel pipette.
2) Remove medium from cells and add to each well 50µl of 1x passive lyses buffer,
place the culture plate on an orbital shaker and shake for 15-20 minutes at room
temperature and then frozen and thawed. 1-2 freeze/thaw cycles are sufficient to
increase the total activity in the lysates, because of more complete lyses.
3) Prepare luciferase Assay reagent II (LAR II) and Stop & Glo ragent (S/G) according
the product information of the Dual Luciferase Reporter Assay kit from Promega.
The LAR II and S/G can be further diluted 5 times without significant effect on the
results. Therefore, prepare the working LAR II and S/G buffers by diluting 5x with
distilled water in a final volume sufficient for the number of wells to be measured
(number of wells x 50µl + 0,5ml. This extra 0,5ml is to load the injector).
4) Transfer 20µl from each cell lysate sample to the measuring plate and load the
Fluroscan Ascent FL (Labsystems) with all buffers.
5) Run the measurement and save all data in Microsoft Excel format.
6) Process the data by calculating the rate between firefly (encoded by pTarget-luc-
HNF4γ) and Renilla (encoded by phRL-TK) luciferase activites and then the average
and standard deviation among the triplicates.
5. 13. 7.  Re-cloning of U6-shRNA expression cassettes into pLentiLox 3.7
The tested constructs with U6-shRNA cassettes form a shuttle system that could be easily
re-cloned in pLentiLox 3.7 used to generate infectious virus particles.
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5. 13. 7. 1.  Releasing of U6-shRNA cassette
The U6-shRNA cassette was released by double digestion with Xba I and Xho I restriction
enzymes. For the set up of the restriction reaction look in “Standard Molecular Biology
techniques”.
1) Incubate the reaction at 370 C for three hours.
2) Purify the released U6-shRNA cassette through 0,8% agarose gel-electrophoresis.
3) Extract the U6-shRNA fragment from the gel (QIAquick Gel Extraction Kit) and
measure its concentration on UV spectrophotometer.
5. 13. 7. 2.  Preparation of pLentiLox 3.7 for cloning of the U6-shRNA cassette
To clone U6-shRNA cassette into pLentiLox vector, the vector must be opened by Xba I -
Xho I and dephosphorilated. !0µg DNA was used for the digestion. For the set up of the
restriction reaction look in “Standard Molecular Biology techniques”.
1) Incubate the reaction for at least for 6 hours at 370 C.
2) Purify the opened vector on 0,7% agarose gel and extract the DNA fragment by
(QIAquick Gel Extraction Kit).
3) Measure the concentration of the open pLentiLox 3.7 vector.
5. 13. 7. 3.  Dephosphorylation of pLentiLox.3,7
For the reaction a 1pmol DNA was used.. For the set up of the dephosphorilation reaction
look in “Standard Molecular Biology techniques”.
5. 13. 7. 4.  Cloning of U6-shRNA cassettes into LentiLox 3.7
For optimal cloning the molar ratio (insert:vector) should be 3:1. For the set up of the ligase
reaction look in “Standard Molecular Biology techniques”.
1) Incubate the reaction at 200 C for three hours and then put it on ice.
2) Transform competent DH10β bacterial cells with 1µl from the ligation reaction.
3) Plate the transformed bacteria on LB agar medium supplemented by Amp and grow
over night to get single colonies.
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4) Prepare plasmid DNA from single colonies (Mini-prep) and analyse them by
analytical digestion with Xba I - Xho I restriction.
5. 14.  Packaging of Lentivirus (LentiLox 3.7)
All steps were done in a S2 facility.
5. 14. 1.  Plating of 293T cell
1) Cell were cultured in the tissue culture plate (15cm x 20mm) at starting density of 1
million in 20ml.
2) Transfer the 293T cells from plate into flask (175 cm2) at seeding density about 6-10
millions in 20ml medium the day before transfection.
5. 14. 2.  Transfection for package of the virus
1) Change the medium of 293T cells in the flask with 18ml of fresh medium 1 hour
before transfection.
2) Mix the plasmids complex with 100µl CaCl2 (2,5M) and ddH2O  up to 1ml.
3) Add 20µl of Chloroquine (10-25µM) to the cells.
4) During the bubbling of the calcium-plasmids complex, a 2x HBSS was drop-wise
added into the complex for the formation of homogenous fine precipitation of DNA-
calciumphosphate complex. The mixture then was further bubbled for additional 10
sec.
5) Add the complex into the flask and incubate the treated cells over night for
transfection.
6) After 16-20 hours, the medium was changed with fresh 10ml to collect the infectious
particles. An another batch of 293T cells were plated in 12 well-plate at density of 5
x 104/ml with 1 ml in each well for measurement of the virus titer at the next day.
7) After 24 hours the conditioned medium of the cells was transferred into Falcon tubes
and centrifuged at 2000 rpm. The supernatant was filtrated through 0,45µm
membrane. The remained cells were re-suspended in 5 ml PBS and measured on
FACS machine. Usually over 90% of living cells give positive signal.
     -Composition of the reagents:
HBSS in use: 100mM HEPES-Na pH 7,11; 280 mM NaCl; 1,5 mM Na2HPO4
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For 20 generation of Lentiviral vector: 40µg vector (pLentiLox 3.7); 26µg Packaging
construct (pCMVdeltaR8.91); 14µg ENV plasmid (pMD2.G)
For 30 generation of Lentiviral vector: 40µg vector (pLentiLox 3.7); 26µg Packaging
construct (pMDLg/pRRE); 14µg ENV plasmid (pMD2.G); 10µg REV plasmid
(pRSVrev)
5. 15.   Generation of RNAi- HNF4γ transgenic mice
Engineered lentiviral particles are microinjected directly into the perivitelline space of
mouse embryos 0.5 days after fertilization. The viral particles are comprised of a self-
inactivating viral vector containing a gene of interest and a promoter, as well as a marker
gene. The particles also contain reverse transcriptase to catalyze the incorporation of the
vector sequence into the genome and the viral particle itself has a glycoprotein coat that
mediates its adherence to the embryo. In some percentage of cases, the viral vector
incorporates into the genome of the one-celled embryo, carrying the gene of interest with it.
Once integrated, the viral sequences cannot be replicated, due to a deletion in the requisite
sequence. Embryos are incubated at 37°C overnight. Two-cell embryos are implanted into
the oviduct of pseudopregnant female mice the following day. Pups resulting from this
procedure are genotyped to test for the presence of the transgene.
-Superovulation and mating of the donor female mice
1) Three days prior to lenti-viral injections, administer 0.1 ml PMS by intraperitoneal
injection to female donor mice (C57BL/6 or FVB).
2) Forty-seven hours after the PMS injection, administer 0.1 ml hCG by IP injection and
pair the females with stud males.
3) Check for plugs the following morning.
-Medium preparation
1) The afternoon prior to injection day, set up two 60 mm culture dish (Corning catalogue
#25382-381) with four 50 µl microdrops of KSOM (Cell and Molecular Technology,
catalogue #MR-101-D) covered with oil, and one 35 mm dishes (Corning catalogue #
25382-348) with three 50 µl microdrops covered with oil. Label each dish with your name
and the date, then place into the CO2 incubator. The medium is incubated overnight to
allow the temperature, and more importantly, the pH to equilibrate.
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3) Just prior to egg harvest on the morning of the injections, add 4 ml of FHM (Cell and
Molecular Technology catalogue #MR-025-D) to a 15 ml conical tube containing 2.6 mg of
hyaluronidase (aliquots stored in the –20 freezer). Invert gently to prevent foam, do not
shake.
-Embryo collection
1) On the morning of injection, sacrifice female donors in groups of five or less, using
cervical dislocation.
2) Collect oviducts and place them into a drop of FHM/hyaluronidase on the bottom of a 60
mm culture dish.
3) Make another FHM/hyaluronidase drop in the same dish.
4) Using two pairs of forceps, gently tear open only those oviducts that have an obviously
swollen ampulla, releasing the egg/cumulus cell bunch into the drop.
5) The remaining oviducts can be flushed using the FHM/hyaluronidase mixture, a 1 cc
syringe and a 32 gauge flushing needle.
6) Transfer the embryos to the 60 mm dish of four drops of KOSM, set out the night before.
Rinse the embryos through the drops until all debris are removed.
7) On Mondays, set aside five embryos as controls. They should remain unmanipulated in
the incubator to ensure that the media, incubator etc. are adequate. In most cases, all five
embryos should develop into blastocysts by Friday. Results are recorded in a log.
-Viral loading
1) Viral aliquots provided by the investigator are kept at –80 C. Take one aliquot of 5-10 ?l
and thaw within a 50 ml conical tube filled with ice. Keep the conical tube in an ice bucket.
Any direct contact with the virus should be done under the hood while double gloved.
2) If dilution is necessary, this should be performed in the hood. The viral titer should be 5
x108 to 5 x 109. If high titer prep is too viscous, it may be diluted 1:1 or 1:2 with ice-cold
PBS.
3) Complete a project record sheet, filling in the viral vector, the gene construct, the date of
injection, the date of preparation, the viral preparer, the injector, and the project number and
replicate number.
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4) In the hood, back-load the injection needle using a long, sterile micropipette tip. Attach
the needle to the needle-holder and, with the needle-holder in the hood, press the flush
button on the injector until the media fills the tip of the needle.
5) Attach the needle-holder with the loaded needle to the micromanipulator and then
exterior gloves prior to continuing with the injection procedure.
-Setting up the microscope
1) Turn on the nitrogen tank
2) Turn on the microinjector (Green switch)
3) Place a set of eggs into a drop of oil-covered FHM in the cooled (4C) injection dish (~30)
Note: Time of egg exposure to FHM (including harvest time) should be no more than one
hour.
4) Place the injection dish in the center of the microscope stage.
5) Focus the microscope at the lowest power on the embryos.
6) Place a holding pipette onto the opposite side of the scope, (e.g., if you are right handed,
the holding pipette should be on the left and the injection needle on the right).
7) Lower both pipettes using the course controls into the injection dish.
8) Maneuver needle and holding pipette so that they are parallel to each other and visible at
the lowest magnification.
-Injections
1) Use the holding pipette to stabilize eggs for injection.
2) Focus on the zona pellucida at the highest power, and inject into the perivitelline space
with adequate volume to see an obvious swelling of the perivitelline space.
3) After ~30 eggs have been injected, place eggs into the 35 mm dish with three drops of
warmed KSOM: Use the first two drops for rinsing to remove residual injection media.
4) Incubate all injected eggs overnight.
5) Unused virus, the injection needles, and the injection dishes should be discarded in
biohazardous waste. The needle holders, the injection dish tray, and all pipetmen used
should be placed in the hood under UV light.
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-Oviduct implant surgeries
1) The next morning count the number of one cell and two cell embryos. The ratio should
be 80/20, two cell to one cell; an indication that the virus was at an optimal concentration. If
the ratio is lower than 80:20, then the virus should be diluted further at the next injection.
2) Transfer the two-cell embryos bilaterally into the oviducts of a 0.5 day pregnant recipient
(See SOP for oviduct embryo transfer).
3) A maximum of 26-30 two cells should be placed into one recipient.
References; [109, 123]
-Oviduct Transfer Protocol
Purpose: To transfer mouse 2-8 cell embryos into 0.5 day pseudopregnant recipient females
for any of several procedures; embryo transfer rederivation, subsequent to in vitro
fertilization, and following pronuclear injections and cryopreservation recovery.
1) Pipette three microdrops (~50 µl) of FHM or M2 media on the bottom of a 30 mm petri
dish.
2) Cover the media with embryo-tested mineral oil and leave at room temperature.
3) After weighing a recipient female, inject the calculated dose of Avertin intraperitoneally.
4) The caudal dorsal area of the anesthetized female is shaved, then scrubbed using
povidone iodine solution or scrub alternately with 70% alcohol on cotton tipped swabs
(repeat two times).
5) Place the prepared pseudopregnant female under the dissecting microscope, ventral side
down.
6) Surgical instruments should be either autoclaved or bead-sterilized. Using a small
scissors and watchmaker forceps, make a 5 mm skin incision. Separate the skin from the
body wall by blunt dissection using scissors tips. Make an incision through the body wall
avoiding nerves and large blood vessels. Manipulate the incision until the white fat pad
surrounding the ovaries is visible. Grasp the fat pad with a dull forceps and pull it through
the incision.
7) Position the ovary for easy access to the oviduct.
8) Pipette enough embryos for one recipient into a microdrop of FHM.
9) Load a transfer pipette (the tip diameter should be only slightly larger than the embryos)
with oil from transfer dish by using mouth suction. Oil level should be close to the
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beginning of the widest part of the pipette. Next, draw a 2-5 mm air bubble into the pipette,
then media with embryos. Carefully press pipette barrel into the clay on the dissecting
microscope until ready to transfer the embryos.
10) Gently tear open the bursa surrounding the oviduct with two pair of forceps allowing
access to the infundibulum, which is the opening to the oviduct. In case of bleeding, use a
sterile cotton swab to gently blot.
11) Once the infundibulum can be visualized, slide the tip of the loaded pipette in and blow
into the pipette until the air bubble is visible within the oviduct.
12) Check the pipette tip underneath the microscope to make sure the embryos have been
transferred.
13) Gently replace the ovary/fat pad and uterus into the abdominal cavity.
14) Close the body wall with one or two simple interrupted sutures of 5.0 silk. The skin is
apposed with one or two sterile surgical clips.
15) The transfer can be done either uni- or bi-laterally. The pups are expected on day 20
following surgery.
5. 15. 1.  Genotyping of the transgenic mice generated by LentiLox 3.7 lentivirus
The genotyping of LentiLox generated mice was done by multiplex PCR using gene-
specific primers for EGFP and appropriate primers giving amplification of the genomic
DNA fragment (encompassing exon 1 from HNF4γ gene) for ensuring the correct PCR
conditions. In addition some of the mice could be genotyped by observing EGFP
fluorescence in the skin.
-Primers used for genotyping of LentiLox-HNF4γ mice
Primers Nucleotide sequence (5´- 3´)
EGFP_N3 (f) TAAACGGCCACAAGTTCAGC
EGFP_N3 ® CGGCCATGATATAGACGTTG
519_F TGTGGTGACAGAGCAACAGG
520_R GACCCAGGATGTATGGACCTT
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-PCR conditions:
N u m b e r  o f
cycles
Temperature Lenght of time
1 cycle 950 C 1 minute
950 C 15 sec
570 C 15 sec
40 cycles
720 C 30 sec
1 cycle 720 C 5 minutes
Figure 33: Genotyping of LentiLox-HNF4γ mice
 (m) DNA Ladder; mice (1, 2, 3, 7, 8, 9, 11, 12, 13, 14) are wt; mice (4, 5, 6 and 10) are positive for
lentivirus integration.
5. 15. 2.  Southern blot of DNA prepared from tails of LentiLox-HNF4γ mice
Southern blot analyses were done with tail DNA (25µg), digested by EcoR I and subjected
for electrophoresis in 1% agarose gel and blotted onto Biodyne B Transfere Membrane
(Pall).  Hybridization was performed with a 32P random labeled by Klenow enzyme 1482bp
EGFP internal probe, released from pLL3.7 by Xho I-EcoR I digestion (For detailed
protocol of Southern blot look in „Standard Molecular biology techniques“).
Figure 34: Southern blot strategy employed for LentiLox-HNF4γ mice
m 1 2 3 4 5 6 7 8 9 10 11 12 13 14
EcoRI
probe
EcoR I chromosome transgene
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5. 15. 3.  Determination of siRNA expression in LentiLox-HNF4γ mice
The siRNA expression in different organs of LentiLox-HNF4γ mice was determined by
Northern blot hybridization. The protocol used includes slight modifications for siRNA
detection.
5. 15. 3. 1.  Isolation of total RNA for Northern blot hybridization
1) Dissect the mouse and take out the organs.
2) Transfer the organ tissue in RLT buffer (Qiagen) supplemented by βMESH in
plastic 50ml Falcon tube. The ratio in the mass solution : tissue must be at least 10:1.
As alternative the tissue could be stored for future use in RNAlater buffer (Qiagen).
Homogenize the tissue by homogenizer immediately.
3) Transfer the homogenate to a fresh polypropylene tube and sequentially add 0,1 ml
of 2M sodium acetate (pH 4.0), 1ml of phenol, and 0,2 ml chloroform-isoamyl
alcohol per ml of the homogenate. After addition of each reagent, cap the tube and
mix the contents by inversion.
4) Vortex the homogenate vigorously for 10 seconds. Incubate the tube for 15 minutes
on ice to permit complete dissociation of nucleoprotein complexes.
5) Centrifuge the tube at 9000 rpm for 20 minutes at 40 C, and then transfer the upper
aqueous phase containing the extracted RNA to a fresh tube.
6) Add an equal volume of isopropanol to the extracted RNA. Mix the solution well
and allow the RNA to precipitate for 1 hour or more at – 200 C.
7) Collect the precipitated RNA by centrifugation at 9000rpm for 30 minutes at 40 C.
8) Wash the pellet by 80% EtOH and dissolve it in appropriate volume of DEPC
treated H2O.
9) Measure the concentration of the RNA.
5. 15. 3. 2.  Electrophoresis of RNA sample on denaturing acrylamide gel
1) Prepare a 15% denaturing acrylamide gel with 7 M urea in 1x TBE within 20x20 cm
mold.
2) Pre-run the gel for 15-20 min at low voltage.
3) Dissolve the RNA (50µg) in 80% formamide containing buffer with dye.
4) Load the RNA on the gel and perform the electrophoresis at 500V -35 mA.
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5) After 2 hours run dismantle the chamber, transfer the gel on Whatman paper and
covered it with Hydrobond-N+ nitrocellulose membrane.
6) Perform electro transfer in special chamber filled with 0,5x TBE under 250 mA (30-
37 V) for about 4 hours.
7) Briefly dry the membrane and fixed it under UV crosslink (auto cross, 1200).
5. 15. 3. 3.  Labelling the probe for Northern blot
Hybridization was performed whit 5´ end 32P  labelled 19 mer (sense) probe specific for
each siRNA. For normalization of the blot a sense 5´32P-labelled oligonucleotide for
endogenous U6 gene was used.
1) Set up the labelling reaction:
Reagents Amount
T4 kinase buffer 10x (Roche) 5µl
T4-PNK (1U/µl) 2µl
Oligo sense probe 2,5µl (5pmol)
γ-32P ATP 3µl
H2O 37,5µl
5. 15. 3. 4.  Northern blot hybridization
The membrane was pre-hybridized in 6 x SSC, 10x Denhardt`s solution and 0,5% SDS at
420 C for 6 hours and hybridized with the probe in 6x SSC and 0,1% SDS over night. At the
next day, the membrane was washed several times first with 6x SSC (3x10 min), then with
2x SSC/0,1% SDS (3x10 min) at 370 C. To reveal the signal from siRNA, the membrane
was exposed on Phospho Imager screen for 2 hours.
5. 15. 4.  Measurement of HNF4γ knockdown in LentiLox-HNF4γ mice by quantitive
real-time PCR
For determination of HNF4γ mRNA in pancreas and intestine, RNA was isolated by
RNeasy Mini Kit 50 (Qiagen) following the manufactures instructions. A 2µg RNA was
reverse transcribed in cDNA by SuperScriptTM First-Strand Synthesis System and Oligo
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(dT)12-18 primer (Invitrogen). The cDNA was purified using QIAquick PCR Purification Kit
(Qiagen) with slight modification of the protocol.
5. 15. 4. 1.  Purification of the cDNA
1) Add 500µl Buffer PB to the cDNA sample and mix.
2) Apply the cDNA mixture to the MinElute column and centrifuge for 1 minute at
13,000 rpm in a conventional tabletop micro-centrifuge.
3) Discard the flow-through. Place the MinElute column into the same collection tube.
4) Add 750µl Buffer PE to the MinElute column into the same collection tube and
centrifuge for 1 minute.
5) Discard the flow-through. Place the MinElute column back into the same collection
tube.
6) Add 500µl 80% ethanol to the MinElute column and centrifuge for two minutes.
7) Discard the flow-through. Place the MinElute column back into the same collection
tube.
8) Open the column caps and place in a microfuge with the cap opposite the direction
of the rotation of the rotor to avoid breaking the cap off. Centrifuge for 5 minutes.
9) Place the MinElute column into a clean, labeled, 1,5mL microfuge tube.
10) To elute cDNA, add 50µl Buffer EB to the centre of the column membrane.
Incubate at room temperature for 2 minutes. Centrifuge for 2 minutes. Discard
column and save the 50µl eluted cDNA.
5. 15. 4. 2.  Real-time PCR conditions
The analyses were done with Mm00443563_m1 (HNF4γ), Mm00660262_g1 (Hmbs)
TaqMan Gene Expression Assays (Applied Biosystems) and Platinum Quantitative PCR
SuperMix-UDG (Invitrogen) onto Light Cycler machine (Roche). The mRNA/cDNA
HNF4γ abundance was calculated relative to the expression of a house-keeping gene
HMBS.
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1) Set up the following reaction.
Reagents Amount
PCR Super mix-UDG
(Invitrogen)
10µl
Bovine serum albumin (10%) 1µl
Taq Platinum (5U/µl) 0,12µl
Gene Assay (ABS) 1µl
MgCl2 (50mM) 1µl
cDNA (1:2 dilution) 7µl
2) Cycling program:
Number of
cycles
Temperature Lenght of time
1 cycle 500 C 2 minutes
1 cycle 950 C 2 minutes
940 C 5 seconds45 cycles
600 C 20 s (single acquire)
5. 15. 5.  HNF4γ protein detection in intestine and pancreas
The HNF4γ/α proteins in intestine and pancreas were detected by immunochistochemistry
using specific antibody on cryo sections. The protocol is described in the section „Standard
Molecular Biological techniques“.
-Antibodies
Molecule/Epitope Sort of antibody Company Working solution
HNF4γ goat polyclonal IgG Santa Cruz
cat#sc-6558
1:500
HNF4α goat polyclonal IgG Santa Cruz
cat#sc-6556
1:900
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5. 15. 6.  Glucose tolerance test
For glucose tolerance test were used A-I (F1) mice and wt mice from the same litters (6
animals per group) at age of 6 moths.
1) Starve the animals over night (16 hours).
2) Next morning measure the weight of the animals.
3) Measure the blood glucose before injection to make sure that levels are low. To take
the samples cut a very small piece of the tail and massage it to get a drop of blood.
4) Inject in to the peritoneum 200µl of the glucose solution (20g glucose/100 ml of 0,9
NaCl) per 20 grams of body weight. Measure the blood glucose levels after 15, 30,
60 and 120 minutes.
5. 16.  Fluorescence imaging
The pictures from organ sections of RNAi-HNF4γ mice were captured by Zeiss-Axioplan
microscope (Zeiss) attached to a Leica DFC 480 Camera (Leica Microsystems) and
supplied by a unit consisting of a mercury lamp and EGFP filter. The whole mount photos
were taken by binocular Stemi SV6 (Zeiss) connected to the light source HBO 100 (Zeiss).
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